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Abstract
The autoimmune disease known as autoimmune thrombocytopenic purpura (ITP) is clinically 
defined by a low numbers of platelets in the circulation blood. Anti-platelet antibodies bind to 
glycoprotein molecules on the membranes of platelets and result in their dysfunction and 
destruction. Despite a growing body of information about ITP, it is difficult to isolate and 
characterise anti-platelet antibodies, because only limited monoclonal antibodies are available 
from ITP patients.
This study used a phage display system to recognise Fab anti-platelet antibodies. Anti-platelet 
Fab-expressing phage was isolated by sequential panning of an ITP Fab library against 
normal non-ITP platelets. After isolation, the anti-platelet Fab-expressing phage was 
characterised by ELISA and Western blotting.
The Fab-bearing phage pool obtained from five rounds of panning was analysed in order to 
determine its anti-platelet reactivity. Of the phage colonies obtained, 100 colonies of 
different sizes were randomly selected for reaction with whole platelets, using M l3 phage as 
a negative control. 12 colonies of them had strong reactions against the whole platelet 
preparation, but only four colonies showed substantial reactivity against the lysed platelet 
preparation (lysate). Colony S7 showed highest the greatest degree of binding to both the 
lysate and the whole platelet preparation. The specificity of the four colonies (S2, S7, S8 and 
S9) that had strong positive reactions against platelet antigens was determined for the 
glycoprotein component GP Ilb/IIIa.
Further characterisation of the proteins in the lysate preparation was carried out using blotting 
techniques. The protein content of the four Fab-bearing phage colonies was quantified under 
the non-reducing conditions of Western blotting to evaluate their ability to recognise platelet 
antigens. Three of the four colonies showed three bands representing proteins with different 
molecular weights. Each of these three colonies had one band that corresponded to a protein 
of molecular weight 92 kD. The fourth colony showed only a single band, but this band also 
corresponded to a 92-kD protein.
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INTRODUCTION
Idiopathic (immune) thrombocytopenic purpura (ITP) is an autoimmune disease that involves 
the development of autoantibodies against platelet cells in the blood, which play an essential 
role in the haemostatic control of bleeding. ITP is characterised by the premature immune 
destruction of platelets, with production of autoantibodies against platelets, specifically 
against the glycoprotein complexes in the platelet membrane, such as GP Ilb/IIIa or GP Ib/IX. 
The glycoprotein complexes are physiological receptors that mediate interactions between 
platelets and vascular subendothelium in injured blood vessels. By their adhesion and 
aggregation activities, the platelets arrest haemorrhaging from lesions in the blood vessel 
wall, and any disruption to their membrane glycoproteins leads to platelet dysfunction and 
destruction, and causes the bleeding disorders seen in ITP. This study aimed to isolate 
autoantibodies made against the platelet glycoproteins using platelets from healthy volunteers, 
to determine their specificity and further elucidate their effects on platelet function. As there 
is no accurate diagnostic test for ITP, new evidence about these autoantibodies may be o f 
great value in the future.
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SECTION I: IDIOPATHIC (IMMUNE) THROMBOCYTOPENIC PURPURA (ITP)
1-1 Features and History of ITP
The main clinical sign of ITP is purpura. Purpura describes a skin disorder involving patches 
o f discoloration that do not blanch (disappear) when pressure is applied. They are caused by 
bleeding beneath the skin because of a failure in some part of the blood clotting mechanism. 
The first descriptions of purpura date back to ancient Greece (Jones 1933), and in the 18th 
century a young woman with spontaneous petechiae and haemorrhages from her nose and 
mouth was described in England (Beutler 1995). The patches on the skin can be purple or red 
in colour and usually measure up to 1 cm across (patches o f less than 3 mm across are known 
as petechiae and those of over 1 cm are known as ecchymoses). Purpura is not a disease, but a 
medical sign with several possible underlying mechanisms. For example, it might be caused 
by a vascular disorder or coagulation disorder, or meningococcal disease or a psychogenic 
problem.
This study is concerned with a coagulation disorder that involves an underlying platelet 
disorder, namely thrombocytopenic purpura. The term "thrombocytopenia" simply refers to a 
low level of platelets (thrombocytes) in the blood circulation o f any cause. An association 
between the presence of purpura in thrombocytopenic patients and platelets was made by 
Simian and Zimmermann in the 19th century, after the observation of "small colourless 
bodies" in their blood. These findings added to scientific advances at that time about the 
processes of fibrin clots, blood coagulation and thrombosis (Bizzozero 1881), and the
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function of platelets and their role in the aetiology of thrombocytopenic purpura gradually 
became clear (Howell 1890; Wright 1906).
The bleeding tendency in ITP is caused by a platelet disorder (White 1994). Because it 
involves a platelet disorder, ITP is known as a thrombocytopathy (Maton 1993) and because it 
involves a decrease in platelet function it is also known as a thrombasthaenia.
There were many cases in which low platelet numbers in patients with thrombocytopenic 
purpura had no identifiable cause, and this form of the disease became to be known as 
"idiopathic" — hence the full name idiopathic thrombocytopenic purpura, or ITP. However, 
Harrington and Hollingsworth established an immune pathogenesis for ITP when they gave 
healthy human volunteers serum from ITP patients (Harrington 1951) and described a 
circulating antiplatelet factor. Further in vivo studies clarified the involvement of IgG against 
platelets (Shulman 1965; Shulman 1965), and it became clear that the numbers of platelets 
drop because they are removed from the circulation. Because of this immune basis of the 
disease, idiopathic thrombocytopenic purpura is also known as immune-mediated 
thrombocytopenic purpura.
1-2 Incidence and Epidemiology of ITP
There are estimated to be 10 to 125 new cases of ITP per million of the population every year 
(George 1996). In the USA, annual rates for adults are approximately 66 cases per million and 
for children are approximately 50 cases per million. There are about 10 cases of chronic 
refractory ITP per million per year. Figures from outside the USA show approximately 10-40
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cases in children per million per year in Denmark and the UK and approximately 125 cases 
per million per year in Kuwait (Silverman 2010).
1-2.1 Race
A genetic influence in the aetiology of ITP is likely, but further studies are required to verify 
the effect of race or ethnicity. There is some evidence that fewer African-American people 
are diagnosed with it (although this might be because the presence of petechiae and 
ecchymoses may not be noticed). A report by (Terrell 2005) added to evidence obtained since 
the 1960s that the proportion of black people with ITP was lower than the proportion of black 
people in the general population of the United States, and that the worldwide occurrence of 
ITP is rare among black Africans and people of African ancestry (Block 1966; Akwari 1987; 
Guthrie 1988; Salawu L 2001; George 2003; Aledort 2004).
1-2.2 Age
Age factors are relevant in the development of chronic and acute forms of ITP, which tend to 
affect different age groups. Around half of the 50-100 new cases seen per million people per 
year are in children, and this tends to be the acute form (platelet counts of less than 27,000 per 
pi), especially in children younger than 10 years old. The chronic form (platelet counts of 
over 27,000 per pi) is generally seen in older patients (Cines 2002). In a major study in 2000 
children aged up to 5 years old from 38 countries, diagnosis o f ITP in children with platelet 
counts of less than 20,000 per pi was shown to peak in the spring and early summer. There
Page | 4
was only a slight difference between boys (55%) and girls (45%) (Kuhne 2001). Age over 10 
years is a risk factor for developing the chronic form of the disease (Watts 2004).
1-2.3 Gender
Childhood cases are roughly the same across genders (Kuhne 2001), but in adults, ITP tends 
to affect more women than men, in a ratio of 1 man to every 1.2-1.7 womaa In adults, with 
an annual incidence of 32 cases per million of the population, the average age of ITP 
diagnosis is 56-60 years (Neylon 2003). It is usually seen in its chronic form in adults, 
occurring particularly in middle-aged women (Cines 2002). Approximately 60,000 adults 
suffer from the chronic form of ITP in the USA alone (Amgen 2008).
1-2.4 Remission
Remission is seen in about 70% of children after 6 months (Ou 2006; Treutiger 2007) and 
some 30% of chronic cases undergo remission during follow-up. Another 30% are left with 
"mild" thrombocytopenia (Watts 2004). In adults, there is a high chance of remission in 20- 
40% of cases (Stevens 2006).
1-2.5 Mortality
The mortality rate of chronic ITP patients varies, but generally it increases with increasing 
age. In a study of ITP patients in the UK, mortality was approximately 60% higher than in 
people without ITP of the same sex and age, with an increased risk of death affecting 96% of 
patients aged 45 years or more (Schoonen 2009).
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1-3 Definition and Types of Thrombocytopenia
Thrombocytopenia refers to low levels of platelets in the circulation, from any cause. A 
normal (healthy) count is somewhere between 150,000 and 450,000 platelets per pi of blood. 
A count of less than 10,000 is usually regarded as a medical emergency, and someone with 
10,000-20,000 platelets per pi will generally receive some kind of treatment. Those with 
counts of 20,000-50,000 are evaluated on a case-by-case basis. However, counts above 
50,000 are not usually treated (Cines 2005).
The accurate diagnosis of the thrombocytopenia in ITP requires exclusion of other kinds of 
thrombocytopenia. There are four types -alloimmune (or isoimmune) thrombocytopenia, 
drug-induced thrombocytopenia, secondary immune thrombocytopenia and autoimmune 
thrombocytopenia (Beutler 1995; Stiene-Martin 1998).
1-3.1 Alloimmune Thrombocytopenia
This can affect newborns (neonatal alloimmune thrombocytopenia) or any patient after a
blood transfusion (post-transfusion purpura). In neonates there is an immune process
involving an "antigen" (the region an antibody recognises and binds to, usually on a foreign
pathogen) known as platelet antigen-1 (PLA1) -  a polymorph of one o f the glycoproteins
found on a particular glycoprotein present on platelet membranes (GP Ilia) -  so this is an
immune process directed against a "self-antigen". Maternal antibodies against foetal platelets
that express PLA1 are formed in mothers who are homozygous for a different platelet antigen,
known as PLA2. These antibodies are then transferred through the placenta into the
developing foetus to cause the disease in the newborn (Barron-Casella 1994). In the post-
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infusion form, differences between the donor's and recipient's alloantigens induce the 
production of alloantibodies against platelets. These antibodies against the donor antigens are 
stimulated by the human platelet antigens (HPA).
1-3.2 Drug-induced Thrombocytopenia
Drug-induced thrombocytopenia occurs with drugs like quinine and heparin. Antibodies may 
be produced against the drug-platelet complex or the plasma protein-drug complex bound to 
platelets, and some drugs cross-react directly with platelets to cause myelosuppression 
(Beutler 1995; Stiene-Martin 1998).
1-3.3 Secondary Immune Thrombocytopenia
This is seen within the context of another primary disease, such as systemic lupus 
erythematosus, rheumatoid arthritis, leukaemia, von Willebrand factor deficiency, 
antiphospholipid syndrome, liver cirrhosis, HIV or hepatitis infections (Beutler 1995; Stiene- 
Martin 1998). Viral infections and other primary causes affect 5-10% of suspected cases 
(Bloom 1981; Cines 2005; Cines 2005).
1-3.4 Autoimmune Thrombocytopenia
Autoimmune thrombocytopenia is the fourth kind of thrombocytopenia, of which idiopathic 
thrombocytopenia is a common presentatioa It is characterised by the destruction of 
antibody-coated platelets in the spleen or the liver, with a normal or slightly increased number 
of the megakaryocytes (platelet precursors) in the bone marrow (Semple 1998).
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1-4 Chronic and Acute Forms of ITP
The disease can be acute and self-limited or chronic, depending on the duration of the 
thrombocytopenia. The acute form lasts for less than 6 months and usually occurs in children. 
The chronic form lasts for years and is usually found in adults (Bloom 1981; Beutler 1995; 
Stiene-Martin 1998). The risk of developing the chronic form can be predicted on the basis of 
platelet counts over 50,000 per pi and age over 10 years (Watts 2004). Immunoglobulins of 
the classes IgA, IgG and IgM are found in varying amounts in the chronic and acute forms of 
the disease.
The pathological mechanism of chronic ITP involves phagocytosis o f platelets via 
autoantibodies after antigens on the platelet surface have become "antigenic". The first 
evidence of such autoantibodies was provided by Leuwen and colleagues (van Leeuwen 
1982). Chronic ITP may also involve complement-mediated lysis and binding of 
autoantibodies to megakaryocytes, with affects on megakaryocyte colony formation and the 
production of platelets (thrombocytes) in the process called thrombopoiesis (McMillan 1978; 
Hoffman 1985).
1-5 Pathophysiology of ITP
While the significance of substances like serotonin and thrombopoietin have yet to be fully 
determined in the pathophysiology of ITP (Yanabu 1991), platelets are well known to be the 
major mechanism behind the development of thrombocytopenia.
Page | 8
Platelet destruction and abnormal platelet development and function bring about the 
characteristic purpura and coagulation disorders seen in ITP (Harrington 1951; Semple 1998), 
and it is the formation o f antiplatelet antibodies that are key to this process (Van Leeuwen 
1982). These antibodies against the body's own components, known as autoantibodies, are 
made specifically against various complexes of glycoprotein molecules in the membranes of 
platelets (Van Leeuwen 1982; Beardsley 1984; Woods 1984). The platelet-specific 
autoantibodies are destroyed by phagocytic cells.
Platelet-specific autoantibodies may lead to enhanced destruction o f platelets, with the spleen, 
the liver and the bone marrow playing central roles in the pathology of thrombocytopenia. 
The spleen is the site of antibody production as well as platelet destruction, the liver is the site 
of destruction in severe cases o f thrombocytopenia, and the bone marrow is the site of 
antibody production (Panzer 1986; Najean 1997).
Antiplatelet antibodies may have other effects. They may trigger platelet activation via 
various receptors on the platelet surface (Anderson 1991; Rubinstein 1991; Bemdt 1993; 
Deckmyn 1998), and may interact with megakaryocytes in the bone marrow and thus impair 
production of more platelets (Ballem 1987; Hasegawa 1995; Nagasawa 1995).
Other factors may be involved in the peripheral platelet destruction seen in ITP. Platelets 
express class I molecules of the major histocompatibility complex (MHC), but some of the 
human leukocyte antigens (HLA) are increased in ITP patients (Helmerhorst 1982; Gratama 
1984; Porges 1985; Mueller-Eckhardt 1989; Nomura 1998).
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A genetic relationship has been suggested between specific platelet alloantigens and 
thrombocytopenia with an autoimmune basis (Song 1997). For example, genes for certain 
antigens of the HPA system (human platelet antigens) have been shown to have associations 
with autoimmune thrombocytopenia and ITP (Song 1997; Thude 1999).
Our understanding of the autoimmune nature of the destruction of peripheral platelets in ITP 
dates back to the 1950s (Harrington 1951; Shulman 1965), but to appreciate this complex 
phenomenon the functioning of the immune system needs to be explained fully.
1-6 Clinical Findings in ITP
ITP is an immune disorder with an autoimmune basis for the thrombocytopenia. Patients with 
ITP may be symptomless, or they may have skin symptoms, as well as a number o f clinical 
and laboratory findings. Signs might include petechiae and purpura (skin rashes) usually on 
the hands or feet, epistaxis (nose bleeds), spontaneous bruising, gastrointestinal bleeding, 
genitourinary bleeding, heavy menstrual bleeding and, in more severe cases, intracranial 
bleeding. However, bleeding is not always seen in chronic ITP patients, even with low platelet 
counts (Olsson 2002). Certain signs that might be expected, like an enlarged spleen 
(splenomegaly), are rarely seen in ITP patients, even though the macrophages that destroy 
platelets are produced in the spleen.
Unfortunately, none of the signs described here are specific for the disease. The bleeding 
disorders usually occur when platelet counts drop to very low levels (less than 50,000 ) but
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laboratory tests are required for making a proper diagnosis (Brighton 1996) as well as the 
exclusion of other forms of thrombocytopenic purpura
1-6.1 Platelet Count
There tends to be a lower peripheral platelet count in patients with chronic ITP (Beardsley 
1989), and this thrombocytopenia occurs because of the shortened lifespan of platelets due to 
increased levels of destructioa However, platelet numbers are more helpful for monitoring 
the progress of ITP patients, rather than for diagnosis, because the diagnosis of ITP does not 
always depend on the absolute number of platelets.
1-6.2 Haematocrit
This is normal in ITP unless bleeding has occurred.
1-6.3 Peripheral Blood Smear
Microscopic examination of a blood film may reveal abnormal platelets. A greater proportion 
will be enlarged (over 2.5 pm) and immature (Bloom 1981). The volume and density of 
platelets are normally unrelated to their age, but after episodes of acute bleeding newly 
synthesised platelets are larger, with increased density and increased content of RNA (Ingram 
1969; Ault 1995). Patients demonstrating high levels of peripheral platelet destruction have 
platelets with a greater mean volume (Martin 1983).
Page | 11
1-6.4 Bleeding Time
Bleeding time is a direct test of platelet function. It is often prolonged in ITP patients with 
minor lacerations or abrasions, but it can be normal in these patients. For this reason it should 
be not used for making the diagnosis of ITP, especially as there are many other diseases that 
cause prolonged bleeding time such as disseminated intravascular coagulation, Bemard- 
Soulier disease and Glanzmann's thrombasthenia (Davidson 2002).
1-6.5 Serotonin Levels
Platelets produce serotonin, store it within granules, and release it when the platelet is 
activated as part of the haemostatic response. There is some evidence to indicate a 
relationship between production of serotonin (5-hydroxytryptamine) and low platelet counts 
in children with ITP (Yanabu 1991). This association is not yet clear, but may have some 
relation to the inhibition of secretion of serotonin from platelet granules by alloantibodies 
(alloantibodies are antibodies against other people's antigens).
1-6.6 Bone Marrow Examination
Usually normal or slightly raised levels of megakaryocytes (the precursors of platelets) may 
be observed (Semple 1998). Megakaryocytes may be enlarged and immature with reduced 
evidence of platelet budding. In patients with a high level of peripheral platelet destruction, 
the megakaryocytic cytoplasm and nuclear DNA increase in quantity. The mean platelet 
volume in bone marrow blood is higher than in peripheral blood (Martin 1983).
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1-6.7 Antiplatelet Antibodies
Some antiplatelet antibodies may be detected in the serum of ITP patients, showing increased 
levels of platelet-associated immunoglobulin (IgG). Assays such as the monoclonal antibody- 
specific immobilisation of platelet antigens (MAIPA) have a specificity o f 80% and an 
accuracy o f 85% (Wadenvik 1998; Winiarski 1998), however platelet antibody assays are 
generally considered unnecessary for diagnosis, although they are useful, and may be 
associated with disease severity. Any studies that characterise autoantibodies against platelet 
glycoproteins in ITP are likely to be useful for making an accurate clinical diagnosis .
1-6.8 Thrombopoietin Levels
Levels of the platelet growth factor thrombopoietin may have some value in ITP patients, 
especially as a marker for differentiating between thrombocytopenia from peripheral 
destruction and from failed thrombocytopoiesis. Levels are slightly raised in ITP patients 
(Kosugi 1996). They are low for any given platelet count, and a deficiency of the hormone 
may be involved in the pathophysiology o f thrombocytopenia (Kosugi 1996; Kuwana 2001).
1-6.9 Reticulated Platelet (RP) Count
These young circulating platelets with a high nucleic acid content can be detected by flow 
cytometry. The number usually rises when the platelet count falls below 6-8 x 1010 per ml 
(Saxon 1998). (Shinjo 2005) found that the number o f reticulated platelets detected by 
automated haematology analysis was significantly raised in patients with ITP. Reticulated 
platelet number allows estimation of megakaryocyte stimulation and platelet production
Page | 13
(Ingram 1969; Kienast and Schmitz 1990; Ault 1992), and may help discriminate between 
thrombocytopenia of different causes.
1-6.10 Mean Platelet Volume
The mean platelet volume (MPV) quantifies the average size of platelets found in blood. The 
average size of platelets is greater when they are being produced in higher numbers than 
normal, so the MPV represents platelet production in bone marrow. The MPV correlates 
strongly with increased platelet production. The mean platelet volume in blood from the bone 
marrow blood is higher than that in peripheral blood (Aliberti 1996). However, results can be 
conflicting. MPV can be very low in thrombocytopenia from impaired platelet production, but 
high in thrombocytopenia with peripheral destruction (as in ITP).
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SECTION II: IMMUNE MECHANISMS
II—1 Immune System and Autoimmune Responses
The immune system is responsible for protecting the human body against pathogenic 
organisms, and can be considered in two parts: innate immune system, comprises the cells and 
mechanisms that defend the host from infection by other organisms, in a non-specific manner, 
and the adaptive immune system, which is composed of highly specialized, systemic cells and 
processes that eliminate or prevent pathogenic challenges. The adaptive immune system is 
composed of the cell-mediated immune response and the humoral immune response (Alberts 
2002). An effective immune response depends on the fine control and regulation o f a complex 
series o f events in both parts (Goldsby 2000). The humoral response involves production of 
antibodies in response to a challenge by an antigen, and it stimulates the cell-mediated 
response. The functioning of the humoral response is fundamental in the pathophysiology of 
HP.
When the immune system reacts to the body's own antigens this is called autoimmunity. A 
"self-antigen" may be recognised by the host's immune cells as a foreign entity and 
autoimmune disease may develop. Genetic and environmental factors are involved in the 
aetiology of autoimmune diseases, such as the antigens of the major histocompatibility 
complex (MHC), defective T-cell function, and the breakdown o f immune tolerance (Moller 
1998), although a genetic basis for ITP has not been established.
Some autoimmune diseases involve antigens that are non-specific, in others they are organ-
specific (Stefanova 2002; Saunders 2007) and in ITP they are specifically against components
Page | 15
of the glycoprotein complexes found in platelet membranes. In chronic ITP, an intravascular 
platelet antigen develops from a self-antigen or foreign molecule. Viruses may have a role in 
the aetiology of autoimmune thrombocytopenia, through some disturbance in the host's 
response, possibly involving platelet injury as a result of antigen-antibody complexes that 
originate from an immune event that is unrelated to the platelet (Kaplan 1992). This is known 
as the "innocent bystander" hypothesis.
The initial immune response occurs in the spleen, which is the prime site for dealing with 
intravascular antigens (Askonas 1958; McMillan 1974; Fujisawa 1993). Antigen-specific 
memory cells develop, leading to a response in which antiplatelet antibodies are created, first 
in the spleen, and later in the bone marrow. These antibodies will be of the immunoglobulin 
class known as IgG. They will bind to platelet-associated antigen to bring about its destruction 
and they will bind to antigens associated with megakaryocyte cells and thus may suppress 
future thrombopoiesis (production of platelets). A number o f cell-mediated immune (CMI) 
reactions will also be stimulated, including the production of protein mediators known as 
cytokines. However, more evidence is needed about the defects in immunoregulation that are 
likely to contribute to the development of ITP (Semple 1995).
II—2 Cell-Mediated Responses
Cell-mediated immunity is the part of the immune response that does not involve antibodies 
or complement proteins. Instead, it involves the activation of macrophages, cytotoxic T cells 
(CD4 cells), and the release of various cytokines. There is some evidence that T-cell-
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dependent cytotoxicity of target platelets occurs (Quagliata 1979), but more information is 
needed about the precise role of the CMI in ITP.
II—2.1 Function of T Cells
T cells provide protection against different pathogens. They are white blood cells, derived 
from the thymus gland, which form an essential part of cell-mediated response. They have 
special receptors on their cell surface called T-cell receptors (TCRs) and there are several T- 
cell subtypes, each with differing functions. These include T helper cells, cytotoxic cells, 
memory cells, regulatory cells (formerly suppressor cells) and gamma delta cells.
T helper cells help out in various immunologic processes. For example, they help B cells 
mature into plasma cells and assist in the activation of cytotoxic cells and macrophages. They 
are also known as CD4+ cells because they express a protein known a CD4 on their surface. T 
helper cells are activated when they react with processed antigens on the surface of antigen- 
presenting cells (APC).
The autoimmune process in thrombocytopenia generally starts after activation of CD4+ 
T helper cells, and the number of cytotoxic (CD8+) cells increases, which may cause an 
imbalance in the immune response. The formation of autoantibodies by B cells is then 
stimulated (Semple 1998). In the case of ITP, pathological antibodies are raised against 
platelets.
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II—2-2 Cytokine Production
Activated T helper cells divide rapidly and differentiate further into more subtypes. The 
precise types of cell formed (ThO, Thl or Th2) will depend on what signals they receive from 
the antigen-presenting macrophages or other APC cells. While the ThO cells are precursors of 
Thl and Th2 cells, the Thl and Th2 cells will start to produce various cytokines. Cytokines 
are small proteins, peptides or glycoprotein molecules that regulate intercellular 
communication and act as cytokines as immune modulators. Examples o f cytokines are the 
interleukins and interferons.
Thl cells secrete interleukin IL-2, interferon gamma (IFNy), granulocyte-macrophage colony- 
stimulating factor (GM-CSF) and tumor necrosis factor alpha (TNFa). Th2 cells produce a 
number of interleukins IL-4, IL-5, IL-6 and IL-10. Patients with ITP generally have higher 
levels of cytokines produced by Thl and Th2 cells as well as cytokines from other sources. 
They include the IL-2, IL-4, IL-6, IL-10 and IL-11 as well as IFA-y, migration inhibition 
factor (MIF), macrophage colony-stimulating factor (M-CSF) and GM-CSF (Joutsi-Korhonen 
2000). Some of these cytokines induce Thl and Th2 cells. MIF is involved in inhibition of 
lymphocytes and migration of macrophages (Clancy 1972). M-CSF induces phagocytosis and 
production of IL-1, and this may contribute to the higher rate o f platelet destruction seen in 
ITP patients (Winiarski 1998).
Three cytokines with a major role in the immune response are platelet-activating factor 
(PAF), platelet-derived growth factor (PDGR) and transforming growth factor (TGF-pi).
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These are chemoattractants for other immune cells like macrophages which are increased in 
ITP.
II—2.3 T cell Activation
The autoimmune process is triggered after activation of T helper cells. There are T-cell 
activators within the alpha-granules of platelets (Andersson 1998) so any damage to platelets 
might contribute to the overall immune response. Activators include the cytokine TGF-pi. 
This inhibits the activation and proliferation of both T and B cells. Any drop in serum levels 
of TGF-pi in people with ITP may therefore lead to increased proliferation of both kinds of 
cells, so T-cell induction of B cells will lead to the production o f more antibodies -  in this 
case against platelets (Andersson 2002).
When ThO and Thl helper cells are activated, changes are observed among the different 
CD4+ helper cells. There is an in vitro reduction in CD4+ suppressor-inducer (regulatory) 
cells, and an increase in CD4+ helper-inducer cells. There are increases in CD8+ cytotoxic 
cells, which are seen as a change in the ratio of CD4+ to CD8+. There are also increased 
numbers of T cells activated by the DR subclass of human leukocyte antigens (the HLA 
system relates to the cell-surface antigen-presenting proteins of the major histocompatibility 
complex, or MHC, in humans). B cells are also induced to produce autoantibodies against 
platelets (Semple 1998).
The in vitro decrease in the T regulatory cell numbers may cause a diminished autologous
mixed lymphocyte reaction (AMLR) in ITP. In fact, the AMLR was markedly decreased in 37
patients with chronic ITP compared to healthy controls in a study by (Deng 1993). The
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percentage of DR+ T cells was significantly increased and correlated inversely with platelet 
counts and AMLR. This might signify some defect in immunoregulation in patients with ITP, 
and may relate to abnormal expression of surface DR+ antigen on non-T cells (Deng, 1993).
II-2.4 Antigen Presentation
T cells are activated by processed antigens on the surface of APCs (e.g.macrophages). There 
are three main types of professional antigen-presenting cell dendritic cells (DCs), 
macrophages and B-cells. Dendritic cells have the broadest range o f antigen presentation, and 
are probably the most important APC. They are present in tissues in contact with the external 
environment, such as the skin (where there is a specialized dendritic cell type called 
langerhans cells) and the inner lining of the nose, lungs, stomach and intestines. They can also 
be found in an immature state in the blood. Once activated, they migrate to the lymph nodes 
where they interact with T-cells and B-cells to initiate and shape the adaptive immune 
response. Activated DCs are especially potent Th cell activators because, as part of their 
composition, they express co-stimulatory molecules such as B7 (Banchereau 1998). They 
express both MHCI and MHC II.
Macrophages are white blood cells produced by the differentiation o f monocytes in tissues. 
Macrophages function in both innate immunity as well as help initiate adaptive immunity of 
vertebrate animals. Their role is to phagocytose cellular debris and pathogens, either as 
stationary or as mobile cells. They also stimulate lymphocytes and other immune cells to 
respond to pathogens. After digesting a pathogen, a macrophage will present the antigen of
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the pathogen to the corresponding Th cells. The presentation is done by integrating it into the 
cell membrane and displaying it attached to an MHC class II molecule.
B-cells, which express (as B cell receptor) and secrete a specific antibody, can internalize the 
antigen, which bind to its BCR and present it incorporated to MHC II antigens.
MHC antigens are also known as MHC moleculesand are coded for by genes in the major 
histocompatibility complex, which relates to the HLA system in humans, a gene-dense region 
of the genome that generates diversity into the immune repertoire. The MHC molecules were 
discovered historically as antigenic factors in organ transplantations, and the major MHC 
antigens are essential for immune function.
There are three classes o f MHC molecules: class I, class II and class III, and each type 
consists o f two polypeptide chains, an a and a p glycoprotein. MHC class I and II are 
expressed on the surface of different kinds of cells, including platelets.
Class I MHC molecules consist of a large glycoprotein a chain (encoded by class I MHC 
genes) and a small invariable protein called p2-microglobulin (encoded by a gene outside the 
MHC). The molecules are expressed on the surface membrane of nearly all nucleated cells 
and platelets. Platelets only normally express class I MHC molecules, however most studies 
on patients with ITP show no change in the frequency of HLA antigens corresponding to 
MHC class I (A, B and C) (McMillan 1980; Gaiger 1994). As there is great variety in the 
amino acid residues of the hypervariable regions of HLA molecules, any differences in HLA 
molecules may affect the development of autoimmune diseases (Janeway 1999).
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Class I molecules present proteins to cytotoxic T cells by forming an MHC-protein complex 
with fragments of protein from any "self' or foreign protein synthesised within the cell, and 
displaying the complex on the cell or platelet surface. It can then be recognised by a T cell. If 
the cytotoxic cell recognises the displayed complex as "non-self' it will destroy the infected 
cell, and any other cells displaying the same protein. A "self-MHC" complex will be 
recognised by immunocompetent T cells and dendritic cells (Janeway 2001).
Class II molecules are heterodimers, consisting of two non-covalently associated 
glycoproteins, the a and p chains. They are encoded by different class II genes. They are 
expressed primarily on the surface membranes of macrophages (APCs) and B cells. They also 
present antigens, this time to T helper cells, inducing them to multiply and stimulate antibody- 
producing B cells to produce antibodies to the displayed antigen, and so stimulating an 
immune reaction from other cells.
Class III molecules are not like class I and IIMHC molecules because they are not membrane 
proteins and they are not involved in antigen presentation (Wonsiewicz 1991). They are 
actually soluble protein products, all of which are all important in the immune process. 
Examples of class III molecules are the proteins of the complement system, tumour necrosis 
factor and the enzyme steroid 21-hydroxylase.
Platelets are associated with many immune-mediated diseases. Platelets from people with ITP 
present peptides from general cellular proteins and platelet-specific proteins to the immune 
system via MHC class I molecules, characterised several MHC class I-associated peptides on 
the platelets of patients with ITP. One of these peptides correlated with the B7 allele o f the
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HLA system, which relates to the platelet membrane glycoprotein GP lb (Hopkins 2005). The 
HLA-associated molecules present the antigen fragments to the T cells, so any changes in the 
HLA system may have an effect on T cell immune function (Janeway 1999).
II—3 Humoral Responses
Antibodies are produced by specialist immune cells known as B cells, which are part of the 
humoral immune process (Pier 2004). The antibody response in ITP involves the 
production of autoantibodies against glycoprotein complexes on the surface of platelets 
(Semple 1998), and leads to disruption of the body's haemostatic mechanisms. The area the 
antibody recognises on a "foreign" particle is known as the antigen (Janeway 2001). In ITP 
this is a distinct region on one of the platelet's glycoprotein complexes. The specific part of 
the antigen that it binds to is called the epitope. When an antigen or self-antigen like a 
platelet glycoprotein is recognised or bound to by an antibody, it becomes "marked" for 
attack by a host of other immune mediators or the antibodies directly neutralise or 
deactivate it (Rhoades 2002; Market 2003).
It is possible that platelet injury occurs with antigen-antibody complexes formed during an 
immunological event that is essentially unrelated to the platelet (the "innocent bystander" 
hypothesis) (Kaplan 1992).
II—3.1 Function of B cells
Autoimmune processes like those involved in ITP generally start after activation of CD4+
T helper cells. T cells stimulate the formation o f antibodies and autoantibodies by other
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white blood cells known as B cells. These cells are produced and mature in the bone 
marrow in humans. The mature cells assist in the activation o f cytotoxic cells and 
macrophages and the synthesise antibody (immunoglobulin), which is displayed on their 
cell membrane. When unbound antigen in the blood attaches to the membrane-bound 
antibody, the B cell is activated (Parker 1993; Verma 2007). The membrane-bound 
antibody forms part of the so-called B-cell receptor (BCR), which will be unique for a 
specific antigen and is a cell-signalling transducer (Wintrobe 2004). When the antigen 
binds to the membrane-bound antibody, it causes the BCRs to cluster together, lifting them 
away from other competing cell-signalling influences on the cell surface (Wintrobe 2004; 
Tolar 2008).
Once activated in this way, the B cells undergo several episodes of proliferation. At every 
stage, the BCRs may be subjected to point mutations, mostly of the substitution types 
(Oprea 1999), thus introducing diversity to the next generation o f cells. Two kinds of cell 
are produced in large numbers. These are plasma cells and memory cells. The memory 
cells serve to "remember" the challenging antigen, which they do for many years so that 
the immune system can react quickly if the same antigen re-enters the body (Borghesi 
2006). The plasma cells produce more antibody.
II-3.2 Antibody Production
The antibody produced by plasma cells usually has the same specificity as the 
immunoglobulin on the surface o f the original activated B cell. There will be some variety
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in the daughter cells because of "class switching" of immunoglobulin class on the antibody 
or because of random mutations (Oprea 1999).
Antibodies are produced in soluble and membrane-bound forms (Parham 2005). The soluble 
antibodies are secreted into the bloodstream and body cavities where they will identify and 
neutralise an enormous range of antigens. The membrane-bound antibodies (also known as 
surface antibodies, surface immunoglobulins, or membrane immunoglobulins) remain 
attached to the membrane of the B cells, ready to attach more antigen. A single cell may have 
50,000-100,000 copies on its surface (Wintrobe 2004). The plasma cells live for only a few 
days, but during that time they secrete up to 2000 molecules of antibody per second, which 
means that an enormous quantity of highly specific antibody is generated.
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Antibody-producing B cells receive information via the macrophages and T cells (Roitt 
1993) and from cytokines such as TGF-pl. This cytokine inhibits the activation and 
proliferation o f T and B cells, so when serum levels drop in ITP patients, there may be 
increased proliferation of both T and B cells. T-cell induction of B cells will in turn lead to 
the production of more antibodies against platelets (Andersson 2002).
Antibodies are known to be produced within the spleen, but they are still found in people 
who have undergone splenectomy (surgical removal of the spleen), which is one of the 
treatments for ITP. This indicates that there are more sites of antibody production, and the 
most likely alternative sites are the bone marrow and other lymphoid tissues.
Antibodies against a component of "self are known as "autoantibodies". They are 
produced like any other antibody, but their contact with their antigenic targets will result in 
a pathological condition in the body. In ITP, pathological antibodies are raised against 
platelets (Semple 1998).
Page | 27
II—3.3 Antibody Structure and Diversity
II—3-3.1 General Structure
Antibodies (immunoglobulins) are heavy, globular, Y-shaped plasma glycoproteins with a 
characteristic sandwich-shaped fold, and a mass of approximately 150 kDa (Litman 1993). 
They are made of sugar chains and amino acid residues, comprising 82-96% polypeptide and 
4—18% carbohydrate (Mattu 1998).
Each antibody contains four polypeptide chains -  two identical heavy chains and two identical 
light chains, connected together by disulfide bonds (Woof 2004). On the arms of the "Y" are 
two distinct regions known as the Fab and Fc regions. The Fc region, which stands for 
"fragment crystallisable", is on the base of the Y and the Fab region, which stands for 
"fragment antigen binding", is on the arm of the Y. On the amino-terminal end of the antibody 
there is a variable region known as the paratope which binds to a specific site on antigen and 
forms part of an "antigen-binding site". Other common structures of antibodies include the 
complementarity determining regions (CDRs) and hypervariable regions.
All antibodies share the same general structure (Woof2004), but the immune system needs 
to respond to the millions o f different antigens found on an enormous range o f bacteria, 
viruses and fungi. Diversity among antibodies is essential for ensuring that an antibody 
exists for any unique antigen on a target pathogen . This structural diversity also means 
that antibodies are produced that are capable of binding to a specific part of a glycoprotein 
complex on the surfaces of a platelet, as in ITP, and generate an autoimmune response.
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II—3.3.2 Structural Diversity
Structural diversity among antibodies is achieved in various ways, primarily involving the 
hypervariable region and thus the antigen-binding sites, some of which are through 
spontaneous genetic means.
II-3.3.3 Variable Regions
Antibodies have a small, extremely variable region of 100-110 amino acids at the tip of 
their amino terminal. This region is known as the hypervariable (or FV) regioa The part of 
the hypervariable region on the amino-terminal end of the antibody that binds to a specific 
site on an antigen is called the paratope. The differences in the hypervariable region relate 
to the loops in four polypeptide chains (known as heavy chains and light chains), with 
structural domains containing 70-110 amino acids (Barclay 2003). The hypervariable 
region is the most important region for binding to antigens. Small differences here produce 
millions of different antibodies. Antibodies containing only one kind of variable region are 
produced by B cells, so all the antibodies secreted from one cell will have the same 
variable region (Janeway 2001; Bergman 2004), but different B cells will produce 
antibodies with different variable regions. Diversity in the variable regions is governed by 
genetic mechanisms.
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II-3.3.4 Heavy and Light Chains
There are two kinds of chain in the antibody -  light and heavy — connected by covalent and 
non-covalent bonds. There are five types of heavy chain, which are known as alpha (a), delta 
(8), epsilon (e), gamma (y) and mu (p). These names correspond with the class of 
immunoglobulin (Ig) they produce, namely IgA, IgD, IgE, IgG and IgM (Janeway 2001). 
They have molecular weights of 50 kD or more and they vary in their amino acid content (450 
to 550 each), size and composition (Janeway 2001). Heavy chains have two distinct regions -  
a constant (C) region and a variable (V) region. The variable region is about 110 amino acids 
long, with just one immunoglobulin domain. In IgM and IgE the constant region contains four 
immunoglobulin domains, and in IgG, IgA and IgD there are three immunoglobulin domains 
in a line together with a hinged region that gives the molecule flexibility (Woof2004).
There are two types of light chain, and these are known as kappa (k) and lambda (X). They 
have molecular weights of about 25 kD, and consist of 211-217 amino acids (Janeway 2001). 
They have one constant and one variable domain.
II-3.3.5 Isotypes
The type of heavy chain determines the antibody's "isotype". Thus the alpha (a) chain is
IgA, the delta (8) chain is IgD, the epsilon (e) chain is IgE, the gamma (y) chain is IgM and
the mu (p) chain is IgM (Janeway 2001). The different isotypes have different functions
and roles in different parts of the immune system. B cells at different stages of
development will produce antibodies with different isotypes (Goding 1978; Market 2003).
Antibodies are also subject to "class-switching" in which the heavy chain changes in
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daughter B cells, producing antibodies with the same paratope but different 
immunoglobulin isotypes.
II-3.3.6 Idiotypes
The "idiotype" of an antibody is determined by the complementarity determining regions 
(CDRs). These form part of the antibody that structurally "complements" a specific 
antigen, so that they fit together like a lock and key, and facilitate antigen recognition by 
immunoglobulin (Li 2004). Three CDRs can be found on the variable (V), diverse (D), 
joining (J) and constant (C) domains of an antibody. Two of them, CDR1 and CDR2, are 
found in the V domain. The third, CDR3, is found on some V domains and some C 
domains and all of the D and J domains. D domains are found on the heavy chains only.
If viruses are involved in the development of autoimmune thrombocytopenia, as has been 
speculated, then it might be through the production of anti-idiotype antibodies (Kaplan 1992). 
There may be a defect in the T-cell induction of antibodies (MoHer 1998) because of T cell 
responses to viral peptides during an infection There may be cross-reactivity between 
structurally similar parts of the viral antigens and platelet glycoproteins in the host (Moller 
1998). There may be a disturbance in the host immune response relating to molecular 
mimicry, production o f anti-idiotype antibodies, enhanced expression of the MHC molecules 
and changes in endogenous antigen (Kaplan 1992). Platelet injury may also result from 
antigen-antibody complexes that arise from an immune event that is not related to the platelet 
(the "innocent bystander" hypothesis).
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II-3.3.7 Fab Region
The Fab region is part of antibody that has direct contact with antigen through the paratope on 
the tip of antibody, so is important in antigen binding. Antibody binding to platelets, and to 
their glycoprotein membrane complexes, can be Fab-mediated (Strieker 1986). The Fab 
region is composed o f one constant and one variable domain from each heavy and light chain 
of the antibody (Putnam 1979) and each Ab has two binding sites for contacting with antigen. 
This means it has enormous specificity for antigens. Fab fragments are easy to isolate and 
produce experimentally, and are useful for characterising platelet glycoproteins.
II-3.3.8 Fc Region and Receptors
The Fc region is composed of two heavy chains with two or three constant domains (Huber 
1980; Janeway 2001). Once binding has occurred, the Fc region recognises opsonised 
particles, causes cell lysis, and induces degranulation o f mast cells, basophils and eosinophils 
(Heyman 1996; Woof2004).
The Fc region binds to specialised protein receptors on an antigen known as Fc receptors.
There are several kinds of Fc receptors (alpha, gamma and epsilon) that differ in their
antibody affinities due to different molecular structures. The gamma subtypes are FcyRI,
FcyRII and FcyRIII. The first of these, FcyRI, has the highest affinity for IgG, binding more
strongly than FcyRII or FcyRIII. It contains an additional immunoglobulin-like domain so it
can be activated by a single molecule of IgG (the other two need to bind more molecules of
IgG to become activated) (Fridman 1991). The Fey receptors are necessary for phagocyte
activation, the release of inflammatory mediators, and mediating the interactions of
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monocytes, phagocytes, macrophages and other cells -  including platelets -  to bring about the 
ingestion, phagocytosis and destruction of IgG-opsonised (coated) particles (Indik 1995)).
On macrophages the Fc receptors mediate the recognition and binding of IgG-coated cells in 
the mononuclear-phagocyte system. This is important in ITP (Karpatkin 1992) because 
platelets coated in IgG will be quickly recognised by Fc receptors on macrophages. The Fc 
portion will fix to the tail of the IgG antibodies and the platelet will be phagocytosed in the 
liver or spleen (McMillan 2000).
II-3.4 Genetic Variability
Antibodies have to recognise epitopes on millions of different antigens in order to generate a 
suitable immune response, and there are a number of ways in which the immune system 
maintains this adaptability and diversity, primarily through genetic means. Much of the 
diversity among antibodies is introduced via the variable region, affecting their antigen­
binding specificity. Random generation of these specificities through genes may contribute to 
the generation of autoantibodies seen in ITP.
The individual domains of each antibody are encoded on specific loci of specific 
chromosomes. In humans, the locus for genes of the heavy chain, for example, is found on 
chromosome 14. For the light chains, they are found on two separate loci on chromosomes 2 
and 22. Individual paratopes are encoded by different gene segments, which are subject to 
random combinations together with random mutations (Diaz 2002; Market 2003).
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Mutations occur during rapid proliferation of B cells, producing thousands of daughter 
cells with slightly different specificities. The cells with the greatest specificity for a 
particular antigen will then be selected to differentiate into antibody-producing plasma 
cells and memory cells.
Four important ways to maintain diversity in the antibody pool are class switching, somatic 
recombination, junctional diversity and somatic hypermutation, as described below. The 
combination o f mutations and gene-based variations in antibody domains introduces 
immense variability (Widmann, 1998). However, hypermutation processes may also be 
involved in a cell "auto-selection" process that leads to the development of an autoimmune 
response.
II-3.4.1 Somatic Recombination
The CDRs in the variable regions of heavy chains are encoded by 65 genes. In somatic 
recombination, these genes combine randomly with the genes for other domains on the 
antibody (Parham 2005). The antibody produced by these developing B cells in the bone 
marrow will have a unique and complete variable region in each immunoglobulin chain, 
adding to the diversity in antigen recognition sites (Li 2004).
The process is also known as V(D)J recombination, because it relates to the regions
encoded in different "gene segments", namely the variable (V), diversity (D) and joining
(J) segments (Nemazee 2006). The D gene segments are short sequences of DNA that join
the V and J gene segments. There is random selection of one V, D and J segment in each
heavy chain (VH, DH and JH) and one V and J segment in each light chain (VL and JL).
Page | 35
Recombination occurs in several stages, so for the heavy chains the DH merges with the 
JH segment to form a DJH segment before combining with the VH segment.
There are multiple copies of each type of gene segment in humans, so the different 
combinations of segments will produce antibodies with different variable regions, with 
different paratopes and different antigen specificities (Market 2003).
II-3.4.2 Junctional Diversity
Junctional diversity occurs during somatic recombination, when gene segments fail to join 
correctly, and introduce variations into the DNA sequence. When the gene segments for 
the variable region are re-arranged, any unused segments are removed, which causes 
breakages between the segments. The broken ends form hairpin loops and join back 
together, but not precisely, resulting in the random addition or subtraction o f nucleotides 
(Janeway 2001). Two recombination activating genes are required, together with various 
DNA repair proteins and enzymes (Wyman 2006).
II-3.4.3 Somatic Hypermutation
These are "point mutations" within the variable regions of the genes for both heavy and 
light chains. They are not completely random (Charles 2005). They tend to occur in the 
hypervariable regions of DNA that correspond to the CDR sites, which govern antigen 
recognition and thus create diversity in the recognition and binding properties of B cells 
(Janeway 2001; Li 2004). B cell receptors undergo these kinds of mutations (mostly 
substitutions) at a very high rate in response to signals from activated T cells (Oprea 1999).
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Hypermutation is complex, involves a number of enzymes at different stages (Bachl 2006; 
Teng 2007), and can result in the production of non-productive genes.
II-3.4.4 Class Switching
The genes for antibodies may be re-organised by "class switching". In this process, an 
activated B cell will have one type of heavy chain but its daughter cells will have a 
different base in their heavy chain. In this way, antibodies will be produced with the same 
paratope but a different isotype, thus having a different function and role from the parent 
B cell.
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Figure III.3 Schematic of CLASS SWITCHING
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SECTION III: PLATELETS
The role of platelets in the pathogenesis o f ITP is complex. When a blood vessel wall is 
damaged, there are interactions between the vessel wall, plasma proteins, and the 
glycoproteins in the platelet membrane that arrest haemorrhaging and limit the vascular 
damage. Autoantibodies against the glycoproteins in platelet membranes disrupt a large 
number o f processes involved in immune function and haemostasis, and are implicated in the 
aetiology of thrombocytopenia with an autoimmune basis such as occurs in ITP.
Ill—1 General Structure of Platelets
Platelets are small, regularly-shaped discoid cells. They measure just 2-3 pm in diameter and 
have a volume of 5-7 femtolitres (Majerus 1994). They do not have a DNA-containing 
nucleus. Their internal structure is complex, consisting of four zones, namely the peripheral 
zone, the sol-gel zone, the organelle zone, and the membrane zone (Fig. III. 1).
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Figure III.4 ultrastructural features of a thin section of the platelet are illustrated. The 
peripheral zone includes the exterior coat (EC), trilaminar unit membrane (CM), and 
submembrane area containing specialized filaments (SMF). The platelet matrix is the sol-gel 
zone which is under the peripheral zone and contains act in microfilaments, structural 
filaments, the circumferential band of microtubules (MT), and glycogen (Gly). The elements 
o f this zone include mitochondria (M), granules (G), and dense bodies (DB).. The membrane 
systems contain the surface-connected canalicular system (CS) and the dense tubular system 
(DTS)(White 1994).
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The peripheral zone consists of the external membranes and the open canalicular system 
(OCS). The OCS is series of fine tubes that extend throughout the zone and connect to the 
outer surface, allowing communication between in both directions between the platelet and its 
environment.
The sol-gel zone is the contractile cytoskeleton of the platelet. It allows activated platelets to 
change from a discoid shape to a stellate shape, with surface projections known as 
pseudopods (Hoffbrand 2001), and causes internal contraction of the cell that cause the 
platelet granules to release their contents. The cytoplasmic domains o f the glycoprotein 
complexes are connected to the cytoskeleton.
The organelle zone contains the metabolic components of the platelet. Among these are 
various granules that contain 30-50% of all the platelet's proteins, and secrete them on 
activation. Dense bodies consist of delta granules that store the potent platelet activator 
adenosine diphosphate (ADP) and adenosine triphosphate (ATP) and contain calcium and 
serotonin taken up from the cytoplasm. Alpha granules contain adhesion molecules like 
platelet factor 4, TGF-01, platelet-derived growth factor, fibronectin, beta-thromboglobulin, 
vWF, fibrinogen and coagulation factors V and XIII. Lambda granules contain hydrolytic 
enzymes. Platelet peroxisomes are involved the production of prostaglandins, and the 
mitochondria (usually seven in each platelet) are important in lipid metabolism (Beutler 
1995).
The membrane zone is the outer plasma membrane layer. It is 7.5 nm thick, with a bilaminar 
structure made up of proteins, lipids (of which 75% are phospholipids) and carbohydrates.
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The membrane bi-layer contains several complexes of glycoproteins (a type of integrin) and 
phospholipids, as well as substances that are important for platelet function, such as calcium 
and an enzyme for producing prostaglandins (White 1994).
Ill—2 Platelet Membrane Glycoproteins Structure and Function
There are at least nine different glycoproteins embedded in the platelet membrane. Among 
them are GP la, GP lb, GP Ic, GP Ila, GP lib, GP Ilia, GPIV, GP V and GP IX. They are 
embedded as complexes. They are all essential for maintaining haemostasis and normal 
immune responses(Beutler 1995; Stiene-Martin 1998). They all act as antigens to
autoantibodies, but the major ones are GP la ,  g p  l b ,  g p  11a ,  g p  l i b ,  g p  111a  a n d  g p  
111b. I n  I T P  these glycoprotein complexes become the self-antigens, a n d  t h e
g e n e r a t i o n  o f  antiplatelet antibodies to the molecules is fundamental to the 
development of thrombocytopenia in ITP.
S o m e  o f  t h e  m e m b r a n e  g l y c o p r o t e i n s  are types o f integrins. They are
embedded as complexes within the phospholipid bi-layer of the platelet membrane and 
connected to the platelet cytoskeleton by their cytoplasmic domains. They have a 
heterodimeric structure, comprising a protein molecule attached to an oligosaccharide 
(carbohydrate) molecule, and two distinct chains known as the a (alpha) and p (beta) subunits. 
The carbohydrate molecule influences the folding of the protein and adds to its stability, and 
the chains form the ligand-binding site.
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They interact with many substances such as collagen, fibronectin, vitronectin, thrombin, vWF 
and collagen, and facilitate adhesion of platelets with the damaged blood vessel wall as well 
as other platelets. They all have essential roles in the immune response in addition to tissue 
repair and homeostasis. Any disruption to their normal function is associated with 
dysfunctional platelet activity and contributes to the development of thrombocytopenia as 
seen in ITP.
The glycoprotein complexes form a range of specific receptors, thus:
• GP Ilb/IIIa complex forms the fibrinogen receptor
• GP aV/GP Ilia complex forms the vitronectin receptor
• GP Ic/IIa complex forms the fibronectin receptor
• GP Ib-IX-V complex forms the vWF receptor
• GP Ia/IIa interacts with collagen.
Ill—2.1 GP Ilb/IIIa Complex 
Structure
The GP Ilb/IIIa complex is a heterodimeric complex. The GP lib subunit is an a-integrin and
the GP Ilia subunit is a P-integrin (Honda 1998), with molecular weights o f 145 kD and 90
kD, respectively (Beutler 1995). The complex provides about 18% of the total proteins o f the
platelet plasma membrane. The GP lib (a) subunit is a transmembrane protein containing four
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domains and a total of 1008 amino acids (Beutler 1995; Bemdt 2000). The GP Iüa (P) subunit 
contains a carboxy-terminal domain, a transmembrane segment, a cysteine-rich A-terminal 
domain, and a total o f762 amino acids. The complex carries HPA-3, HPA-9 and Va.
The subunits are produced separately, then combined in a calcium-dependent process to form 
the complex within the rough endoplasmic reticulum (Tomiyama 1993; Beutler 1995)). The 
complex then binds to the transmembrane domain of the platelet via non-covalent calcium- 
dependent bonds (Page 1991; Bemdt 2000).
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Figure III.2 Schematic of the Glycoprotein Ilb/IIIa Complex
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Figure III.5 Schematic diagram of the GP Ilb/IIIa heterodimer complex. The fibrinogen 
binding site is located on both subunits of the glycoproteins. The binding site for the 
tripeptide RGD sequence (arginine-glycine-aspargine) is on GP Ilia. GP Ilia also contains the 
human platelet antigens HPA-1, HPA-4, HPA-6, HPA-7, HPA-8, HPA-10, -Groa and -Oea. 
HP A-3 and HPA-9w are located on GP Ilba (National Institute for Biological Standards and 
Control, 2002a).
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Function
The GP Ilb/IIIa complex is involved in the immune response and haemostasis and is one o f 
the most studied platelet glycoproteins. It functions as a receptor for soluble fibrinogen in the 
plasma, so it has a major role in thrombus formation in a damaged blood vessel. Two main 
regions in the fibrinogen molecule interact with a binding site on the complex. These are the 
RGD (the recognition sequence for the tripeptide amino acid arginine-glycine-aspargine) and 
the carboxy-terminal of the gamma chain. Interactions between both of these regions with the 
Gp Ilb/IIIa complex are necessary for the thrombus to form (Page 1991; Honda 1995; Bemdt 
2000). This interaction is shown in Fig. III.2. The calcium-binding site of GP Ilb/IIIa may 
also act as a calcium channel in platelets (Rosado 2001).
When a platelet is activated, the complex undergoes a conformational change that makes 
fibrinogen bind to it with high affinity (Wagner 1996). The conformational change causes 
GP Ilb-IIIa to be displayed differently on activated platelets. This interaction between the 
receptor and fibrinogen initiates the formation of a haemostatic plug, or clot. More platelets 
are then induced to aggregate in the subendothelium of the damaged blood vessel where they 
bind with vWF, vitronectin and fibronectin. However, if a compound containing or mimicking 
an RGD sequence links to the complex, it enhances the display of the complex on resting 
platelets or masks the thrombin-induced increased display of the complex (Marder 1993). 
Either way, it inhibits platelet activation. However the reaction can be reversed by adding 
more fibrinogen (Page 1991).
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The binding of fibrinogen to activated platelet also induces the expression of new epitopes 
on the GP Ilb/IIIa complex. These are called ligand-induced binding sites, or LIBS (Shattil 
1985) and they are involved in transmembrane signalling (Honda 1995). Three distinct 
LIBS have been identified. Two are on the GP lib subunit (one on the carboxy-terminus of 
the heavy chain and one on the A'-terminus) and one is on the GP Ilia subunit. The ligand­
binding activity of the GP Ilb/IIIa complex depends on the change in the GP Ilb/IIIa 
complex from an inactive state to an active state. This is induced by ADP and antiplatelet 
antibodies. As well as the conformational changes of the complex, the membrane 
undergoes certain modifications (Shattil 1985; Bemdt 2000). Then the coup lex is able to 
transfer information from the inside of the platelet to the outside (Tohyama 1998), and this 
leads to a series of biochemical reactions, such as phosphorylation of cytoplasmic proteins 
in the cytoplasmic domain of the GP Ilia subunit by protein kinase C. Another 
conformational change follows in which the platelet cytoskeleton is rearranged, releasing 
activation factors from the alpha granules and dense bodies so that secondary aggregation 
occurs (Bemdt 2000; Rosado 2001). As a consequence, more molecules o f GP Ilb/IIIa are 
exposed on the platelet membrane, and more fibrinogen binds to it (Hillery 1991; Law 
1996). This situation involves both inside-outside and outside-inside signalling, and links 
ADP with activation of the GP Ilb/IIIa integrin. The LIBS, fibrinogen and RGD all 
contribute to the formation of fibrin clots (Frelinger 1990).
Role in ITP
The GP Ilb/IIIa complex is highly immunogenic, with several autoepitopes and
alloantigens, and clinically important polymorphisms (Beardsley 1984; Woods 1984;
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Woods 1984; Tomiyama 1987; Tomiyama 1989; Kunicki 1992; Kokawa 1993). There is 
evidence that the lib component is involved in the aetiology of autoimmune 
thrombocytopenia (Stiene-Martin 1998; Kahn 1999; Moran 2000). Autoantibodies against 
the self-antigens in this complex are common in the sera of ITP patients (Van Leeuwen 
1982; Beardsley 1984; Woods 1984).
III-2.2 GP Ia/lla Complex 
Structure
The structure of the GP Ia/IIa complex is shown in Fig. III.3. It has two subunits, the la 
subunit (a2) and the Ila subunit (ßl), joined by non-covalent bonds. Both subunits consist of a 
single polypeptide chain with intra-chain disulfide bonds. The GP la subunit contains a 
transmembrane domain plus a short cytoplasmic segment and two human platelet antigens 
(HPA-5 and Sita). There is a collagen-binding site on the N  terminus. (National Institute for 
Biological Standards and Control, 2002).
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Figure III.6 Schematic of the Glycoprotein Ia /lla  Complex
PGIIa
Collagen binding site
PGIa
Figure III.6 The divalent, cation-dependent GP Ia/IIa complex showing the location of the 
human platelet antigens (HPA-5 and Sita) and the collagen binding site (National Institute for 
Biological Standards and Control, 2002b).
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Function
The GP Ia/IIa complex is an adhesion receptor and it acts as a collagen receptor. It has an 
important role in clot formation, promoting the adherence of platelets to the subendothelium 
of the blood vessel. Through its interactions with collagen, it tethers the platelet to the wall of 
the blood vessel wall and prevents them from being detached by the high shear stress exerted 
by the flowing blood. In conditions of high shear stress in the blood vessel, GP la adheres to 
vWF and the blood vessel subendothelium(Moroi 1997).
III-2.3 GP Ib/IX/V Complex
Structure
This hetero-oligomeric protein complex is produced from four genes. In this complex, GP lb 
is non-covalently associated with both GP IX and GP V. The GP IX and GP V components 
are non-covalently linked to GP lb in a ratio of 2:2:1 (GP lb to GP IX to GP V). The GP lb 
subunit is the largest fragment, with 610 amino acids and a molecular weight of 170 kD. It is 
composed of one a  subunit (with a molecular weight of 144 kD) and one p subunits (with a 
molecular weight of 26 kD), linked by disulfide bonds. Both subunits are integral to the 
platelet membrane and contain cytoplasmic components (Macintyre 1987; Feng 2000; Moran 
2000). Fig. III.4 shows the structure of the complex and the location of the alloantigens, HPA- 
2 on GP Iba, and Ly8 on GP Ibp. GP Iba is related to actin-binding proteins in the sub­
membrane of the platelet. The vWF and thrombin binding sites are on the N terminus 
(National Institute for Biological Standards and Control, 2002c).
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Figure III.7 Schematic of the glycoprotein Ib/IX/V complex
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Figure III.7 Schematic diagram of the non-covalently associated GP Ib-TX-V complex, 
showing the locations of the human platelet antigen HPA-2 on GP Iba, and the Ly3 antigen on 
GP Ibp, and the vWF- and thrombin-binding domain sites on the N terminus. GP Iba is also 
related to actin-binding proteins in the sub-membrane of the platelet (National Institute for 
Biological Standards and Control, 2002).
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Function
The GP Ib/IX/V complex forms the receptor for vWF, therefore it is involved in interactions 
with vWF, as well as thrombin and actin, and facilitates platelet adhesion to vascular 
subendothelium after vascular injury. It initiates signalling events within the platelet that lead 
to enhanced platelet activation and thrombus formation. There are approximately 11,000 
copies on each platelet (Kahn 1999). It is also expressed on the precursors of platelets -  
megakaryocytes.
III-2.3.1 GP lb Subunit
The GP lb component is involved in platelet interactions with vWF and thrombin through its 
extracellular domain. It also has binding sites for actin in its short cytoplasmic region. The 
globular protein, actin, forms microfilaments within the cytoskeleton, giving mechanical 
support to the cell and securing the cytoplasm within its surroundings to facilitate signal 
transductioa The actin-binding protein binds to the carboxy-terminal of the GP lb 
component, and accelerates the aggregation response to vWF. During platelet activation the 
binding protein is degraded by endogenous calcium-activated proteins. Then GP lb can move 
freely and facilitate the adhesion of platelets to immobilised vWF and the blood vessel 
subendothelium.
The adhesion of unstimulated platelets to vWF in the subendothelium of the damaged vessel
wall (George 1984) occurs after a conformational change in the GP lb that is brought about by
high shear stress exerted by blood as it passes the tethered Gp Ib/IX component. Normally,
platelets only interact with vWF bound to a solid surface under conditions of high shear rates
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(found in arteries and arterioles) (Weiss 1978). This is a shear-dependent response and it may 
be regulated by the cytoplasmic tail of GP lb (Macintyre 1987). When the GP lb component is 
blocked with monoclonal antibodies, platelets do not adhere well to the subendothelium, 
regardless of the amount of shear stress. GP lb may also function as a binding site for 
thrombin (Macintyre 1987).
III-2.3.2 GP V Subunit
This component is leucine-rich and has a molecular weight of 82 kD. It has high affinity for 
thrombin and an important role in thrombin signalling (Macintyre 1987; Moran 2000). It may 
have a role in the interaction of platelets with vWF (Modderman 1992). Some studies suggest 
it is necessary for the functioning of the entire GP Ib-IX complex (Kahn 1999), but it does 
not seem to be essential for the surface expression of the functional complex (Macintyre 
1987; Moran 2000).
III-2.3.3 GP IX Subunit
The GP IX component is a small membrane glycoprotein of just 160 amino acids and a 
molecular weight of 22 kD. It is a heterodimer of two polypeptide chains (alpha and a beta) 
linked by disulfide bonds, and consists of a transmembrane domain and a small cytoplasmic 
tail (Macintyre 1987; Kahn 1999; Moran 2000). It forms a 1:1 non-covalent complex with 
GPIb.
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III-2.3.4 GP Ib/IX Subunit
The GP Ib/IX subunit has numerous carbohydrate molecules consisting of chains of sialic acid 
residues. The chains contribute significantly to the negative charge of the platelet surface, 
attracting enzyme complexes containing tenase and prothrombinase that are important in the 
coagulation process. Through its interactions with vWF, it promotes adhesion and tethers 
platelets to blood vessel walls to form a plaque, so they are not detached by shear stress from 
blood as it flows past (Kahn 1999). In conditions of high shear stress, GP Ib/IX adheres to 
vWF and the blood vessel subendothelium.
Role in ITP
The GP Ib/IX/V complex contains a number of alloantigens and autoepitopes as well as some 
major polymorphisms. It is highly immunogenic (Kunicki 1992; Ouwehand 2000) and its 
target antigens have been extensively studied (Van Leeuwen 1982; Beardsley 1984; Woods 
1984; Woods 1984; Tomiyama 1987; Tomiyama 1989). Some studies indicate that GP lb is a 
possible target antigen in both drug-induced and autoimmune forms of thrombocytopenia 
(Stiene-Martin 1998; Kahn 1999; Moran 2000). Increased plasma levels of glycocalicin 
(which is cleaved from the extracellular region of GP lb and released into the plasma) are 
associated with thrombocytopenia caused by platelet destruction-associated, so measurements 
(the so-called "GC index") may help differentiate immune thrombocytopenia due to increased 
platelet destruction from that due to impaired production, and it may distinguish different 
types of ITP (Fujisawa 1993; Stiene-Martin 1998; Wadenvik 1998).
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I ll—2-4 GP Ic/IIa Complex
Structure
The GP Ia/IIa heterodimeric complex is a non-covalent complex of glycoprotein subunits Ic 
and Ila and is found within the membranes of intact platelets. Its molecular architecture is like 
that of the Ilb/IIIa molecule (see above). It is expressed on a variety of cell types in addition 
to platelets.
Function
This complex forms the fibronectin receptor. It facilitates adhesion of cells to fibronectin (via 
the RGD sequence) and the adhesion of inactivated platelets to fibronectin-coated surfaces 
(Macintyre 1987; Beutler 1995; Stiene-Martin 1998). The Ic subunit consists of disulfide- 
linked heavy and light chains with iV-linked oligosaccharides.
Disruption of this receptor will result in disruption in the adhesion of cells to fibronectin and 
inactivated platelets to fibronectin-coated surfaces.
III-2.5 GP aV/IIIa Complex
Structure
This GP V component contains an alpha chain (aV) which is the CD51 antigen. The Ilia 
subunit is CD61, which is a 110-kD component composed of heavy chains and kappa light
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chains (Modderman 1989a; Modderman 1989b). Between 50 and 100 copies o f the complex 
are expressed on each platelet. It is also found on endothelial cells.
Function
This complex forms the vitronectin receptor. It mediates activation-independent cell adhesion 
to vitronectin, vWf, fibrinogen and thrombospondin (an extracellular glycoprotein inhibitor of 
angiogenesis). Adhesion to vitronectin only occurs in the presence of magnesium or 
manganese. On endothelial cells, the binding of adhesion proteins is inhibited by RGD 
peptides (Macintyre 1987; Tomiyama 1993; Beutler 1995; Stiene-Martin 1998).Vitronectin- 
mediated adhesion is likely to be disrupted.
Ill—3 Other Platelet Antigens and Integrins
The glycoproteins contain various antigenic structures, some o f which are involved in 
immune-mediated thrombocytopenia. Many of these are human platelet antigens (HPAs) 
which are significant in the immune responses to blood transfusion because they can trigger 
production of platelet-specific alloantibodies against donor antigens. The glycoprotein 
complexes GP Ia/IIa, GP Ib/IX/V, GP lib and GP Ilia contain many HP As. The thirteen 
known ones are HPA-1 through to HP A-10, Ly4, Sita, —Groa and —Oea'
Other antigens on the surface of a platelet may evoke production of antibodies. These include 
the human leukocyte antigens (HLAs) and the A and B antigens o f the ABO blood-typing 
system.
Page | 56
I ll—3.1 Human Leukocyte Antigens
The human leukocyte antigen (HLA) system relates to the cell-surface antigen-presenting 
proteins o f the major histocompatibility complex (MHC) in humans). It is important in the 
immune response and the pathogenesis of certain autoimmune diseases. There are HLA 
molecules on approximately 73% of platelets in humans (George 1985; Taaning 1992; Daci 
1995) expressed on the platelet surface as different classes of MHC molecules. Platelets 
normally express only class I MHC molecules, where they present fragments of proteins to 
T cells for attack. Immune responses to the HLA antigens are significant because any 
disruption will affect T cells. In addition, there is great variety in the amino acid residues of 
the hypervariable regions of HLA molecules, and any differences in these can affect the 
development of autoimmune diseases (Janeway 1999).
MHC class I-associated peptides are present on the platelets of healthy people and patients 
with ITP (Hopkins 2005). Most studies on ITP patients show no change in the frequency of 
HLA class IA, IB or IC antigens (McMillan 1980; Gaiger 1994).
Ill—3.2 ABO Blood-Type Antigens
These antigens are most relevant to transfusion reactions and transfusion-induced 
thrombocytopenia.
Page | 57
I ll—3.3 O ther Integrins
Some of the glycoproteins integrins are very immunogenic and are involved in the 
pathogenesis of ITP, but there are other types of integrin on the surface o f platelets that are 
important in the immune response and for tissue repair and homeostasis. These integrins 
mediate attachment between platelets, cells and tissues, as well as transmembrane signalling 
in both directions (outside-in and inside-out via the OCS), in a process that involves tyrosine 
phosphorylation and alterations of intracellular calcium and pH (Honda 1998; Tohyama 
1998). Because the transfer is in two directions, integrins allow rapid and flexible responses to 
conditions in the environment. Integrins can switch between different activation states 
depending on the signalling they are involved in.
All platelet integrins are heterodimeric proteins formed from an alpha (a) and beta (p) 
subunit. There are at least seventeen a  and eight P integrin subunits (Page 1991; Peterson 
1998) which occur in at least 24 combinations, providing platelets with sufficient diversity to 
recognise a range of adhesion molecules (Ruoslahti 1991).
Ill—4 Platelet Maturation and Function
III—4.1 Development
Platelets are produced in the bone marrow, by budding off from the cytoplasm of 
megakaryocyte cells. The highly specialised megakaryocyte cells undergo fragmentation in a 
process known as thrombopoiesis. Megakaryocytes are derived from haematopoietic stem 
cells by a process known as endoreduplication, in which their DNA is replicated but their
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cytoplasm does not change, so the cells mature but do not divide (Branehog 1975). The 
undeveloped megakaryocytes have a single large nucleus that occupies the majority o f the cell 
volume, but the cytoplasmic content increases during maturation. A smooth internal 
membrane develops within the megakaryocyte which will form the external membrane of the 
platelets as they bud off. There are several cycles o f endoreduplication before the 
megakaryocyte breaks down into platelets, leaving a denuded nucleus. A single mature 
megakaryocyte can produce between 5,000 and 10,000 platelets. Sometimes there are 
increased levels of bone-marrow megakaryocytes in ITP patients (Semple 1998) but often 
they are within the normal range.
The regulation of megakaryocyte development and platelet formation takes place at many 
levels, governed by various cytokines (Kaushansky 1995), but the process of platelet 
production (known as thrombopoiesis) is stimulated by the glycoprotein hormone known as 
thrombopoietin. Thrombopoietin (TPO) is a megakaryocyte growth and development factor 
produced by the liver and the kidney. It regulates the production of platelets by the bone 
marrow, by stimulating the production and differentiation o f megakaryocytes (Kaushansky 
1995).
This platelet growth factor influences overall platelet mass (Kaushansky 1995). It is produced 
in the liver and kidneys and controls the rate of production by pushing haematopoietic stem 
cells through the various stages of the cell cycle (Ritchie 1996), and it causes the 
megakaryocytes to undergo proliferation and differentiation. It also reduces apoptosis o f 
megakaryocytes (Ritchie 1996).
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The normal range o f platelets is 150-450 * 109 per litre of blood (that is, 150,000-450,000 
cells per pi) of blood (Kuter 1996). Platelet count quantifies platelet production, but other 
methods include platelet turnover and megakaryocyte mass. Megakaryocyte mass relates the 
number of platelets in the bone marrow to their volume (calculated from their mean diameter).
Ill—-4.2 Production
Platelet counts in people with ITP are generally low. Generally there will be an increase in 
megakaryocyte mass, and the relationship between platelet turnover and megakaryocyte mass 
can indicate the severity o f the thrombopoiesis. Platelet turnover is increased in ITP patients, 
but because some types of platelets may be more resistant to immune destruction, this 
turnover data cannot be taken at face value.
In the thrombocytopenia seen in ITP patients, some o f the reduction in circulating platelets 
may involve inhibition of platelet development. Current thoughts relate to the impaired 
production of the platelet growth factor, thrombopoietin. This hormone is responsible for 
stimulating platelet production, so any defect in its production will directly influence platelet 
production. Thrombopoietin levels are found to be higher in patients with low levels of 
platelet production than in those with high levels of peripheral platelet destruction (Porcelijn 
1998) and only slightly higher than in healthy people (Kosugi 1996). Because of its potential 
involvement in the aetiology of platelet depletion disorders, thrombopoietin is now a target 
for specific drugs called thrombopoietin receptor agonists. Short peptides with the same 
actions as thrombopoietin may be synthesised chemically. There may also be some
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dysfunction of B or T lymphocytes during thrombopoiesis, and possible an increase in 
activation of mononuclear phagocytes.
Platelet antibodies may also affect the megakaryocytes in the bone marrow. Since 
megakaryocytes carry the same antigens as mature platelets, platelet antibodies may interact 
with the megakaryocytes leading to impaired platelet production. In chronic ITP, 
autoantibodies bind to megakaryocytes (McMillan 1978; Hoffman 1985) and these 
autoantibodies may cause damage directly to the precursors, in which case platelet 
development will be affected. They may also disrupt megakaryocyte colony formation and 
production of lymphocytes (McMillan 1978; Hoffman 1985). However, binding of 
autoantibodies to megakaryocytes has only been shown in vitro .
In some diseases in which there is depletion o f platelets in the circulation, which can happen 
very quickly, the bone marrow may increase platelet production many times over in order to 
maintain a normal platelet count.
III—4.3 Distribution
There is significant variation in the number of platelets in different parts o f the body. 
However, the total number o f platelets in the body usually remains the same (Kuter 1997). 
About two-thirds, or 70%, of platelets are found within the blood circulation at a 
concentration o f 150-400 x 109 per litre. About 30% remain in the spleen circulation. The 
overall average platelet number is 90 x 106 per litre of blood (Kuter 1996).
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Circulating levels in the blood can be depleted very quickly, even in healthy people. In fact, 
an average healthy adult must produce about 2 xlOn platelets every day to keep the 
circulating level constant. The bone marrow can increase platelet production five- to ten-fold 
to achieve this (Majerus, 1994).
Platelets live in the circulation for 5-9 days before being removed by phagocytosis in the 
reticular endothelial cells of the spleen and liver.
III-5 Role in Haemostasis
Platelets have a complex part to play in haemostasis. When a blood vessel wall is damaged, 
and the subendothelium is exposed, a series of interactions between the blood vessel wall, 
plasma proteins and the platelet -  particularly the glycoprotein complexes in its membrane -  
will take place. Ultimately, the haemorrhaging of the injured vessel will be stopped and 
vascular damage will be limited. Platelets are essential for maintaining haemostasis o f the 
body, by causing bleeding to stop, and this is primarily by clot (thrombus) formation.
People with low blood platelet counts can bleed excessively or there can be bruising or the 
formation of petechiae as in ITP. Conversely, if the platelet counts are too high blood clots 
can form easily and can block the blood vessels, resulting in a cerebrovascular accident, 
myocardial infarction or pulmonary embolism.
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I ll—5.1 Clot Formation
When the endothelial cells on the inner surface of a blood vessel are injured, the 
subendothelial matrix of the damaged blood vessel is exposed. A number o f other 
subendothelial factors are then exposed to the bloodstream where the platelets are circulating. 
These factors include collagen, vWF, laminin, fibronectin and tissue factor. When the 
circulating platelets make contact, they are activated. Activation causes a cascade o f reactions 
that causes the platelets to stick to the site o f injury in the blood vessel. This is primarily 
mediated by the glycoprotein complexes on their surface membranes. The large multimeric 
glycoprotein, vWF, is a cell adhesion ligand that helps the endothelium bind to collagen. 
Fibronectin is an extracellular matrix glycoprotein that binds to the receptor proteins known 
as integrins spanning the outer membrane of platelets. These glycoprotein receptors mediate 
further reactions that contribute further to platelet activation, adhesion and aggregatioa The 
platelets clump together and form clots, and the glycoproteins on adjacent platelets bind with 
circulating fibrinogen to strengthen the thrombus (Wilson 2005). The clot ultimately forms a 
haemostatic plug that stops the flow of blood from the injury site.
Ill—5.2 Surface Receptors
The membrane of the platelet contains several complexes of glycoproteins and phospholipids, 
as well as substances that are important for platelet function, such as calcium and an enzyme 
for producing prostaglandins (White 1994). The glycoproteins act as receptors for platelet 
activators and mediate adhesion reactions. There are at least nine different glycoproteins
(GP la, GP lb, GP Ic, GP Ha, GP lib, GP Ilia, GP IV, GP V and GP IX) and they are all
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essential for maintaining haemostasis and immune responsiveness (Beutler 1995; Stiene- 
Martin 1998). In ITP, autoantibodies are made against these glycoproteins. The membrane 
phospholipids attract coagulation proteins and act as the substrate for enzymes that produce 
thromboxane.
III-5.3 Thromboxane
Thromboxane is a type of lipid known as an eicosanoid. The enzyme thromboxane-A 
synthase, found in platelets, converts the arachidonic acid derivative, prostaglandin H2, to 
thromboxane. Two major types -  thromboxane A2 and thromboxane B2 -  are produced by 
activated platelets. On activation, there is an increase in the production of phospholipase A2. 
This causes the formation of TXA2 (Rand 1998), which stimulates activation of more 
platelets and facilitates platelet aggregation. How they are secreted from platelets is still 
unclear.
Thromboxane acts by binding to thromboxane receptors and it facilitates platelet aggregatioa 
It activates other platelets by binding with specific sites on their surface. The platelets change 
shape and intracellular calcium levels increase, inducing protein phosphorylation. Protein 
kinase C is activated, and induces the expression o f the glycoprotein GP Ilb/IIIa glycoprotein 
on the platelet membrane. This is the fibrinogen receptor (Francischetti 2000) and it mediates 
platelet aggregation is achieved when circulating fibrinogen binds these receptors on adjacent 
platelets. As a result, a clot forms (thrombosis).
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I ll—5.4 Platelet Activation
When platelets are activated, a host of chemical and structural changes occur that are central 
to the haemostatic process.
III-5.4.1 Conformational Changes
During platelet activation, the contractile cytoskeleton of the platelet induces the platelet to 
change from a discoid shape to a stellate shape and form surface projections known as 
pseudopods (Hofibrand 2001). The long extensions help structurally in the aggregation of one 
platelet with another.
Another conformational change occurs in the cytoskeleton through internal contraction and
rearrangement of the cytoplasm causes the platelet granules to release their contents. The
delta granules in the dense bodies secrete activation factors like the potent platelet activator
ADP. The alpha granules secrete the activation factors and adhesion molecules such as
platelet factor 4, TGF-01, platelet-derived growth factor, fibronectin, beta-thromboglobulin,
vWF, fibrinogen, factor V and factor XIII. The lambda granules secrete enzymes. Fibrinogen,
for example, is released into the OCS and into the bloodstream, where it binds to receptors on
adjacent platelets and strengthens the forming clot (Wilson 2005). Fibrinogen is also
converted by thrombin into fibrin, a major constituent of clots, which binds to fibronectin.
Fibronectin also binds to integrins and collagen. The vitronectin promotes cell adhesion and
cell spreading. Secondary aggregation follows as a result (Bemdt 2000; Rosado 2001) and
consequently more molecules of GP Ilb/IIIa are exposed on the platelet membrane, to bind
more fibrinogen (Hillery 1991; Law 1996) and stimulate the release of more ADP and hence
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activate further molecules of the glycoprotein complex. This inside-outside and outside- 
inside signalling means the LIBS, fibrinogen and RGD all contribute to the formation of fibrin 
clots (Frelinger 1990)
When platelets are activated by ADP, the GP Ilb/IIIa complex on its surface undergoes a 
conformational change that causes it to be displayed differently on activated platelets, with 
the expression of new epitopes that allows fibrinogen to bind with a high affinity (Wagner 
1996), and contributes to the formation of a haemostatic plug, or clot. However, if a 
compound containing or mimicking an RGD sequence links to the complex, it can mask this 
increased display or instead enhances the display on resting platelets (Marder 1993), thus 
inhibiting platelet activation (Page 1991).
When platelets are activated by ADP and antiplatelet antibodies, the GP Ilb/IIIa complex 
adopts an active state (Shattil 1985; Bemdt 2000). It then expresses new epitopes on its 
surface, two on the GP lib subunit and one on the GP Ilia subunit. These ligand-induced 
binding sites (LIBS) are involved in transmembrane signalling (Honda 1995), and enable the 
complex to transfer information from the inside of the platelet to the outside (Tohyama 1998), 
and lead phosphorylation of cytoplasmic proteins in the cytoplasmic domain of the GP Ilia 
subunit by protein kinase C.
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I ll—5.4.2 Biochemical Changes
During platelet activation, phospholipid molecules are transported to the surface membrane, 
mediated by an enzyme known as scramblase. These phospholipids provide a negatively 
charged surface that attracts enzyme complexes that aid in the coagulation process. Two 
important complexes contain the enzymes tenase and prothrombinase. Tenase is an activating 
complex made up o f tissue factor, factor VII, and calcium. Prothrombinase forms a complex 
with factor X.
On activation, actin-binding protein within platelets is degraded by endogenous proteins. The 
actin microfilaments are in the cytoskeleton where they support the cell structure and secure 
the cytoplasm within its surroundings, thus facilitating signal transduction. The GP lb subunit 
of the GP Ib/IX/V complex normally binds to the actin at its carboxy-terminal. When the 
actin-binding protein is degraded, the GP lb can then move freely, which facilitates the 
adhesion of platelets to immobilised vWF and the blood vessel subendothelium.
ADP released from the dense bodies (Rand 1998) can bind with a specific group of receptors 
on the surface of other platelets and activate even more platelets (Murugappa 2006). There are 
three receptors for ADP on platelets. One receptor is ionotropic and is involved in the influx 
of calcium ions. Another is a protein-coupled receptor that is involved in the platelet's shape 
change and activation of phospholipase C. The third is another protein-coupled receptor that 
mediates the inhibition of adenylate cyclise (Francischetti 2000).
Page | 67
Finally, during platelet activation, there is an increase in the production of phospholipase A2, 
which induces the formation of TXA2 (Rand 1998). This stimulates activation o f more 
platelets and facilitates platelet aggregation.
III-5.4.3 Inhibition of Platelet Activation
Platelet activation can be inhibited when the tripeptide RGD links to the GP Ilb/IIIa 
(fibrinogen receptor) complex on the surface of a platelet (Page 1991). In normal haemostasis, 
it can also be inhibited by substances like nitric oxide, prostacyclin PGI 2 and endothelial- 
ADPase from the thin endothelial layer inside blood vessels. The enzyme endothelial- 
ADPase, for example clears away the highly potent platelet activator, ADP (Rand 1998). The 
eicosanoid prostacyclin PGI 2 directly inhibits platelet activation (Robbins 2010).
III-6 Dysfunction and Destruction
III—6.1 Dysfunction in ITP
Blockade of platelet function can occur during thrombopoiesis, possibly through increased 
activation of mononuclear phagocytes.
In ITP patients, antiplatelet antibodies cause both platelet destruction and platelet dysfimctioa 
The antiplatelet antibodies formed in ITP are linked with platelet dysfunction. Platelets 
function abnormally as a result of autoantibodies that recognise antigens on their surface 
(such as their surface glycoprotein complexes) and bind to FcyRII receptors (Rand 1998). 
They inhibit platelet adhesion and platelet aggregation (Yanabu 1993; Wadenvik 1998)
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examined the sera from ITP patients. They found that the IgG autoantibodies inhibited platelet 
aggregation when they reacted with a 24-kD membrane glycoprotein (Yanabu 1993). Sera 
from ITP patients that contains antibodies against the glycoprotein complex GP Ilb/IIIa has 
been found to inhibit the platelet activator, ADP. It also inhibits collagen-induced 
aggregatioa
Some antiplatelet antibodies are also associated with prolonged secondary platelet 
aggregation (Zahavi 1974). Because the process is prolonged, it will gradually deplete the 
contents o f the platelet granules, such as ADP and ATP, and may cause a storage deficiency 
(Colman, Kuchibhotla et al. 1977; Yanabu 1991).
The capacity of platelets to form a clot may also be affected, because aggregation in response 
to ADP and collagen will become blocked, resulting in increased bleeding time. In ITP 
patients, antibodies against the glycoprotein GP lb subunit can inhibit the binding of vWF to 
GP lb, thus disrupting the clotting response that is started by vWF. Furthermore, the 
interaction between platelets and collagen will be inhibited (Komecki 1990; Christie 1992).
There is some controversy about the effect of antiplatelet antibodies on platelet function. 
Some antibodies isolated from sera o f ITP patients have been shown to inhibit platelet 
aggregation, but similar antibodies from other patients have been shown to activate platelet 
function (Hashimoto 1994; Taylor 2000). Aggregation assays carried out with antiplatelet IgG 
isolated from the serum of an ITP patient reacted with glycoproteins with molecular weights 
of 55 kD and 49 kD, but there was a long delay before aggregation occurred. When 
antiplatelet antibodies were induced by ADP, aggregation was rapid (Caprino 1974).
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III-6.2 Destruction in ITP
Platelets have a mean lifespan of 7-10 days in normal healthy people. They are usually 
destroyed in the spleen by macrophages, or in the liver by Kupffer cells in the liver in more 
severe cases (McMillan 2000). Circulating platelets in people with ITP are destroyed by 
phagocytosis or complement-induced lysis. In conditions with increased peripheral platelet 
destruction, the survival of platelets ranges from a few days to a matter of minutes. They can 
be destroyed by antibody-mediated phagocytosis or by lysis. This platelet destruction involves 
complement activation and binding o f antibody to megakaryocytes which decreases platelet 
production.
ITP patients who have undergone splenectomy may still show thrombocytopenia, so other 
organs of the reticulendothelial system may be involved, such as the liver (Panzer 1986; 
Najean 1997).
Ill—6.2.1 Phagocytosis
Platelets in ITP are destroyed by the mononuclear phagocytic system, although additional 
mechanisms may be involved in some subsets of ITP patients.
Phagocytosis depends on the formation of specific antibodies. The process is initiated by the 
Fc regions on the tail of IgG autoantibodies. The Fc region interacts with both the Fc 
receptors and various proteins o f the complement system, such as C3b fixed on the cell 
surface. The CR1 and CR3 complement receptors and Fc receptors regulate the phagocytic
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process (Karpatkin 1992). The Fc receptor called FcyRI has very high affinity for binding 
IgG.
The IgG-containing antiplatelet antibodies are directed against various glycoprotein receptors 
in the platelet membrane (Schwartz 2007). In ITP patients, this process may depend on 
fixation of complement proteins C3, C4 and C9 in ITP (McMillan 2000). The platelets 
become coated with IgG autoantibodies. When they become coated during this opsonisation 
process, platelets are marked for ingestion by phagocytosis, usually by macrophages 
(McMillan 2000). They are recognised by macrophage Fc receptors and may activate 
complement. Phagocytosis usually begins when the Fc portion of IgG or C3b is fixed to the 
surface (Karpatkin 1992).
Activation of the complement cascade results in complement-induced lysis, thus the severity 
of thrombocytopenia in ITP may depend on the ability of antiplatelet antibody to fix 
complement, as well as the amount of antibodies coating the platelet, and the activity of the 
Fc receptors
III-6.2.2 Lysis
Lysis describes a type of cell destruction in which the cell is broken down by compromising 
its integrity, by viral, enzymatic, or osmotic means. The process can be mediated by proteins 
of the complement cascade. Antibodies fix complement to platelets.
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Complement-mediated platelet lysis in ITP has not been well documented clinically, but 
increased rates of lysis have been observed in vitro (McMillan 2000). It may depend on the 
ability o f antiplatelet antibody to fix complement, and determine the severity o f 
thrombocytopenia. Platelet lysis in vivo was observed in one with ITP associated with 
monoclonal IgM antiplatelet antibodies . In the presence o f fresh serum, antiplatelet 
antibodies induced fragmentation and lysis of platelets in vitro and generated pro-coagulant 
platelet microparticles, but this did not happen when the serum was heated, suggesting that 
complement is involved in this antibody-mediated process . In another study, antibodies 
specific to epitopes of GP Ilia from a patient with ITP and HIV generated peroxide-induced 
platelet damage, with platelet fragmentation, procoagulant release, and thrombocytopenia.
Lysis of platelets also leads to the release of glycoproteins from their membranes. This means 
new epitopes are exposed, and new autoantibodies can be produced against the glycoproteins. 
A mechanism like this may be important for the pathogenesis of platelet abnormalities in ITP 
patients.
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SECTION IV: ANTIPLATELET ANTIBODIES IN ITP
IV-1 Autoantibody Induction in ITP
ITP is an autoimmune disease in which platelets are self-antigens, stimulating production of 
antiplatelet antibodies. In ITP patients, the self-antigens are the glycoprotein complexes on 
the surface o f platelets. It has been long-established that this antiplatelet factor is located in 
the IgG fraction (Shulman 1965), and that IgG is produced by the spleen (McMillan 1974). 
Patients with ITP show increases in circulating and splenic CD5+ B cells and CD 19+ 
B lymphocytes in both the circulation and the spleen, and the increase correlates with the 
production of antiplatelet antibodies. Autoreactive T helper cells are significant in the 
development of autoimmunity, and there is evidence that abnormal activity o f T cells 
stimulates the production of the platelet autoantibodies seen in ITP (Semple 1991; Stasi 2008; 
Yu 2008). T helper cells also induce lymphocytes to produce various immunoglobulins, 
including subtypes o f the IgG class, namely IgGl, IgG2, IgG3 and IgG4. They initiate 
somatic mutations in the variable (V) region of genes, which important in the pathogenesis o f 
autoimmune diseases (Janeway 2001).
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Platelets
Figure III.8 Emergence of antiplatelet antibodies. Platelet proteins are cleaved into peptides 
by an antigen-presenting cell (APC) and expressed on the APC cell surface via MHC class II 
molecules. The T-cell receptor (TCR) of the T helper cell can then bind the peptide-MHC 
complex and signal activation that upregulates CD 154 (CD40 ligand) to interact with CD40 
on the APC, so that additional co-stimulatory interactions occur. The activated T helper cell 
produces cytokines (interleukin-2 and interferon-y) that promote B-cell differentiation and 
antibody production. (Beardsley 2006).
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In chronic ITP the autoimmune process involves the production of specific antiplatelet 
antibodies in the spleen and bone marrow. An intravascular platelet antigen forms, either from 
a self-antigen or from some particle on the surface of the platelet. The autoimmune response 
is initiated, first in the spleen and then in the bone marrow (Askonas 1958; McMillan 1974; 
Fujisawa 1993) with the development of antiplatelet antibodies and antigen-specific memory 
cells.
Antiplatelet antibodies are usually directed against the glycoprotein complexes on the platelet 
surface. Around 25% of autoantibodies in ITP patients are against different membrane 
glycoproteins or glycolipids, and they are known to be mostly of the IgG immunoglobulin 
type (Shulman 1965; Shulman 1965; McMillan 1974). Some of these autoantibodies will 
attach to the glycoprotein epitopes on the external membrane of the platelets and bring about 
their destructioa These interactions were demonstrated in various studies of 
thrombocytopenia and platelet destruction and the enhanced production of platelet-binding 
IgG in cells from ITP patients (Semple 1998; Wadenvik 1998). IgG-specific autoantibodies 
can be detected in about 60% of ITP patients (Coopamah 2003).
Other immunoglobulin isotypes, such as IgA and IgM, are also produced in the platelet 
autoantibodies both the chronic and acute forms of ITP (He 1994). Quantifying these 
autoantibodies may allow immune thrombocytopenia to be distinguished from 
thrombocytopenia of non-immune cause (Wadenvik 1998; Winiarski 1998).
The platelet-specific autoantibodies cause both platelet destruction and platelet dysfunction in
ITP. Monoclonal antibodies specific for the glycoprotein complex GP Ilb/IIIa activate
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platelets via the platelet FcyRIIA receptor (Anderson 1991; Rubinstein 1991; Bemdt 1993) 
and lead to increased Fc-receptor-mediated destruction of platelets in the peripheral 
circulation by macrophages. Antiplatelet antibodies also affect the megakaryocyte precursor 
cells within the bone marrow, by reacting with antigens on their surface that are also found on 
mature platelets. This cross-reactivity can cause impaired platelet production. Around 20% of 
patients with ITP have impaired megakaryocyte function and reduced platelet turnover 
(Ballem 1987; Nagasawa 1995). People with ITP who have GP Ib-specific antibodies in their 
serum still have normal numbers of megakaryocytes, but the cells are smaller than those 
found in patients with GP Ilb/IIIa-specific antibodies. It seems likely, therefore, that GP Ib- 
specific antibodies impair platelet production (Hasegawa 1995). There is also impaired 
megakaryocyte function in patients with ITP (Ballem 1987), and in the chronic form there is 
some evidence of autoantibody binding to megakaryocytes.
A weak genetic association has been suggested between autoimmune-mediated 
thrombocytopenia and alloantigens for platelets. For example, associations have been found 
between autoimmune thrombocytopenia and the HPA-5a5b genotype in GP la, and chronic 
refractory ITP and HPA-2a (Song 1997).
IV-1.1 T and B Cell Interactions
Various abnormalities of cellular immunity have been reported in chronic ITP. Some 
antibody-mediated autoimmune diseases develop because of a defect in the T-cell induction 
of antibodies (Moller 1998), possibly related to the response o f T lymphocytes to viral
peptides during a viral infection (Kaplan 1992; Moller 1998). T cells are generally thought to
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start the production of the autoantibodies, and abnormal T cell activity has been associated 
with the production of the antiplatelet antibodies seen in ITP (Semple 1991; Stasi 2008; Yu 
2008), along with antigen-presenting cells in the early stages. Changes are observed in the 
ratio of T cells expressing CD4+ and CD8+, with an increase in the proportion of CD8+ cells.
Auto-reactive T helper cells are known to be significant in the development of autoimmunity, 
and are activated through the binding o f antigens to the T-cell receptor (TCR) and the co­
receptors CD4, CD3 and CD45 (Janeway 2001). Platelets are the primary source of 
autoantigens for the stimulation of T helper cells in ITP, and T helper cells have been found to 
initiate the production of autoantibodies against platelets in the disease (Hedlund-Treutiger 
1998). There is a reduction of CD4+ suppressor-inducer cells and an increase in CD4+ helper- 
inducer cells and HLA DR+-activated T cells (Semple 1998). A decrease in the T-suppressor 
cell population may be the cause o f the diminished AML (autologous mixed lymphocyte) 
reaction observed in ITP patients.
IV-1.2 T Helper Subtypes and Cytokines
The T helper subtypes ThO, Thl and Th2 T helper cells produce various cytokines. These
include the lymphokine factors, interleukins IL-2, IL-4 and IL-5, interferon gamma (IFNy)
and tumour growth factor beta (TGF-p), In chronic ITP, the activation of ThO and Thl cells
stimulates an increase in HLA DR+-activated T lymphocytes. This in turn induces production
of antiplatelet antibodies from B cells (Semple 1998). The humoral immune response is also
affected in ITP patients. During the development of antibodies, T helper cells react with
processed antigens on MHC class II molecules that are found on APC cells. Platelet antigens
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are processed into smaller peptides fragments within phagolysosomes, before being 
transferred onto the surface of macrophages with the help from MHC class II molecules 
(Semple 1998). In ITP patients, peptides from platelet-specific proteins and other general 
cellular proteins are presented to the immune system via MHC class I molecules. In 
thrombocytopenia due to increased peripheral platelet destruction, platelets normally only 
express MHC class I molecules. Various HLA types, responsible for presenting peptide 
fragments of antigens and self-antigens to T lymphocytes, have been reported to be increased 
in several studies (Helmerhorst 1982; Gratama 1984; Nomura 1998), but in most patients with 
ITP there is no change in class I antigens such as HLA-A, HLA-B or HLA-C (McMillan 
1980; Gaiger 1994). Any differences in HLA molecules are likely to have an impact on 
autoimmune responses (Janeway 1999). Although direct correlation has been between 
glycoprotein-specific autoantibodies for Ilb/IIIa and Ib/IX and two DRB1 HLA antigens in 
ITP patients (Nomura 1999; Kuwana 2001), no strong relation has so far been observed 
between ITP and the HLA genes (Taaning 1992).
When the T lymphocytes recognise the antigen in association with MHC molecules, the
B cells are activated. An increase HLA DR+-activated T lymphocytes induces the production,
via ThO and Thl cells, of antiplatelet antibodies from B cells (Semple 1998). Another subset
of T helper, known as Th2 cells, activate specific B lymphocytes, causing them to proliferate
and differentiate into antibody-producing plasma cells. There is cross-linking by antigen of
membrane immunoglobulin on the surface of B lymphocytes. ThO and Thl cells are activated,
stimulating an increase in HLA DR+-activated T lymphocytes. This in turn induces production
of antiplatelet antibodies from B cells (Semple 1998). Increases are observed in
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B lymphocytes expressing CD5+ and CD 19+ in both the circulation and the spleen, with a 
significant increase in circulating and splenic CD5+ B cells that correlates with the production 
of antiplatelet antibodies.
The release of certain cytokine factors from T helper cells is also essential to the activation of 
B cells. These include the interleukins IL-2, IL-4 and IL-5. The factors IL-4, IFNy and TGF-P 
released from Th2 cells induce a switch of the p chain in B lymphocytes to yl, y2, y3 or y4 
chains. T helper cells also induce lymphocytes to produce various immunoglobulins, 
including various subtypes of the IgG class, namely IgGl, IgG2, IgG3 and IgG4. They initiate 
somatic mutations in the variable (V) region of genes, which is a key process in the 
pathogenesis of autoimmune diseases (Janeway 2001). Approximately 70-85% of patients 
with ITP or suspected ITP have positive platelet-associated IgG (Christopoulos et al., 1993), 
and platelet-specific IgG has been detected to GP Ilb/IIIa and GP Ib/IX in patients with 
thrombocytopenia (Brighton 1996).
The autoantibodies in ITP are produced against the epitopes of glycoprotein complexes on the 
surface of platelets. They bind to platelet FcyRII receptors (Rand 1998) and when coated with 
IgG autoantibodies, the platelets undergo opsonisation. These glycoprotein complexes are all 
important in normal haemostasis and clot formation, and the bleeding disorders seen in ITP 
are caused by disruption of their interactions in haemostasis. Further characterisation of the 
specific glycoprotein complexes affected in ITP will clarify their role in the disease process.
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IV-2 Detection of Antiplatelet Antibodies
There are many assays for detecting autoantibodies and platelet-associated antibodies in 
serum, with direct assays for platelet-bound immunoglobulins on the surface of intact 
platelets. Measures of platelet-associated immunoglobulin and glycoprotein-specific 
antiplatelet antibodies are widely used in investigations of ITP (Mueller-Eckhardt 1989). In 
antigen capture assays, solubilised platelet antigens are immobilised on plastic wells and are 
exposed to an antibody. Monoclonal antibodies for specific platelet proteins can help 
determine the targets o f antiplatelet antibodies. The specificity of platelet-associated IgG for 
different platelet glycoproteins on the platelet may be detected (Berchtold 1993).
IV-2.1 Enzyme-Linked Immunoassay (ELISA)
ELISA is widely used and a range of methods are used. They all involve attachment of a 
platelet suspension to microtitre wells as a monolayer or detergent lysate antibodies tagged as 
ligands with peroxidase or alkaline phosphatase. Commercial ELISA kits can be used to 
detect glycoprotein-specific antibodies in samples o f serum ELISA has been used to detect 
GP Illa/IIb autoantibodies on whole platelets and platelet lysate (Brighton 1996) and it has 
also been used to quantify IgG and demonstrate the role of platelet-associated IgG in the 
inhibition of platelet aggregation in ITP patients (Yanabu 1993; Hasegawa 1995; Nagasawa 
1995).
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IV-2.2 Flow Cytometry
Flow cytometry is a technique for counting and analysis of the physical or chemical properties 
of particles such as cells. Cells are suspended in a stream of fluid and passed through an 
electronic detection apparatus. The specificity and sensitivity of the method for diagnosis are 
greatly increased if glycoprotein-specific mouse monoclonal antibody is used. Flow 
cytometry can be used to detect the young circulating platelets known as reticulated platelets, 
and platelet-associated IgG in ITP.
IV-2.3 Immunobead assay
An immunobead assay uses plastic beads coated with an antigen or antibody that aggregates 
or agglutinates in the presence o f a specific antibody or antigen. The assay has been used to 
detect platelet-associated IgG in ITP and GP IV-specific platelet-associated IgG. However, 
the assay is subject to methodological and practical limitations.
IV-2.4 Immunoblotting
Antiplatelet antibodies can be detected in serum samples by an immunoblotting assay. The 
technique involves immobilising proteins from a cell culture or tissue sample on special 
membranes before various monoclonal or polyclonal antibodies are applied (Towbin 1979; 
Burnette 1981). There are different blotting techniques, such as dot blotting and western 
blotting. In western blotting, electrophoresis is used to separate out proteins o f different
Page | 81
masses on a gel, before transferring them onto a membrane to be probed with specific 
"marker" antibodies (Burnette 1981).
IV-2.5 Modified Antigen Capture ELISA (MACE)
In the MACE technique, platelets from patients (or control platelets) are added to microtitre 
plates coated with monoclonal antibodies to capture specific immune complexes of platelet 
glycoproteins and antibodies. It has been used to detect anti-GP Illa/IIb autoantibodies on 
whole platelets and platelet lysate and anti-GP Ilb/IIIa and anti-GP Ib/IX platelet-associated 
IgG in patients with non-immune thrombocytopenia and ITP. It can detect the specificity of 
platelet-associated IgG for different glycoproteins on platelets (Brighton 1996).
IV-2.6 Monoclonal Antibody Immobilisation of Platelet Antigen (MAIPA)
MAIPA is sensitive, reproducible, assay with a high specificity that gives consistent results 
(Wadenvik 1998; Winiarski 1998). It is widely used, but it has methodological and practical 
limitations. For example, it has been known to give false-negative results if there are low 
platelet counts or low levels o f antibody or antibody without specific for the major platelet 
glycoproteins. The principle involves incubating patient platelets with bound autoantibody (or 
controls) with mouse monoclonal antibody for a platelet surface antigen. The monoclonal 
antibody is captured so that the surface glycoprotein-antibody complex can be immobilised 
and detected using an IgG probe. MAIPA can be used to identify autoantibodies on whole 
platelets and platelet lysate (Brighton 1996) it is one of the best methods for distinguishing 
between immune and non-immune forms of the disease. It can detect GP Ilb/IIIa-specific
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platelet-associated IgG and GP Ib/IX-specific platelet-associated IgG in patients in samples 
from thrombocytopenic patients with and without an immune basis (Brighton 1996). 
Glycoprotein-specific platelet-associated IgGs have been shown to occur in significantly 
different percentages in patients with ITP compared to patients with non-immune 
thrombocytopenia (Brighton 1996).
IV-2.7 Platelet Immunofluorescence Tests (PIFT)
The method is relatively insensitive, but it is often used for quantifying platelet-associated 
IgG in the diagnosis of ITP. Platelets from the patient are incubated with fluorescence- 
labelled anti-IgG, anti IgM and anti-IgG. In the direct PIFT assay, fixed platelet suspensions 
are incubated with anti-human antibody which it can analysed by flourecence microscope. 
Platelet-associated IgG, IgM and IgA were detected in 92%, 42% and 9% of patients with 
ITP, respectively and the technique has been used to show platelet-associated IgG in 70-85% 
of patients known to have ITP (Christopoulos 1993).
IV-2.8 Platelet Radioactive Antiglobulin Test (PRAT)
In this quantitative antiglobulin consumption assay, radioactive-labelled anti-IgG is bound to 
IgG on the surface of the platelet. Investigations of ITP often rely on measures of platelet- 
associated IgG (Panzer 1986).
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IV-3 Autoantibodies to Platelet Glycoproteins in ITP
When lysed platelets release glycoproteins from their membranes, autoantibodies are 
produced against the exposed epitopes of the glycoproteins. Such autoantibodies are found in 
approximately 60% of ITP patients (Coopamah 2003) and these are mostly specific (more 
than 90%) for the IgG isotype (Schwartz 2007). The glycoprotein complexes all act as 
receptors for substances that mediate the haemostatic response, and all are essential in normal 
clot formation. Disruption therefore leads to disordered haemostasis and the kinds of bleeding 
disorders seen in ITP. Around 25% of autoantibodies found in ITP patients are for different 
membrane glycoproteins and glycolipids. The binding of the glycoprotein autoantibodies is 
not spread widely over the glycoprotein complexes. They attach to limited regions or epitopes 
on individual glycoprotein subunits, to specific sequences or to the amino or carboxy 
terminal
IV-3.1Anti-GP Ilb/IIIa Antibodies
IV-3.1.1 Findings in ITP
The majority of antiplatelet antibodies (75%) are made against antigens on the GP Ilb/IIIa and 
GP Ib-IX complexes (VanLeeuwen 1982; Beardsley 1984; Woods 1984). Autoantibodies for 
the GPIIb/IIIa complex are sometimes measured in high levels and are detected in 
approximately 15% of patients. Two studies have demonstrated GP Ilb/IIIa-specific 
antibodies in approaching 90% of ITP patients. One patient with a bleeding disorder had
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GP Ilb/IIIa-specific autoantibodies together with GP IV-specific and GP Ia/IIa-specific 
autoantibodies (Beer 1993).
Determining whether autoantibodies attach to the GP lib or GP Ilia subunits is not easy 
(Yanabu 1991), but the autoantibodies are known attach to limited regions on both of the 
glycoprotein subunits. (Kosugi 1996) identified as cation-dependent regions of GP Ilb/IIIa as 
autoantigenic targets of platelet-associated IgG.
Binding o f anti-GP Ilb/IIIa autoantibodies is usually to the GP lib subunit, at its amino­
terminal end. They also bind to epitopes that are close to calcium-binding sites (McMillan 
2000) .
Sometimes autoantibodies attach to the GP Ilia subunit in the cytoplasmic region o f the 
carboxy-terminal end (Bowditch 1995). GP Ilb/IIIa-specific platelet-associated IgG have been 
shown to bind to the amino acids 35-50 of the GP Ilia subunit. There is some evidence that 
they attach to cation-dependent epitopes on the GP Ilia component, but only if the whole 
GP Ilb/IIIa complex is conformâtionally intact. Other proposed targets include a 33-kDa 
cysteine-rich region, and amino acids 73-39 (McMillan 2000).
IV-3.1.2 Effects of Disruption
The GP Ilb/IIIa complex forms the fibrinogen receptor and is involved in the im m un s  
response and regulation of haemostasis. It is one of the most studied glycoprotein complexes 
and one of the most immunogenic, with several known autoepitopes and alloantigens, and 
some clinically important polymorphisms (Tomiyama 1987; Kunicki 1992; Ouwehand 2000).
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Serum from ITP patients with these autoantibodies can inhibit the platelet activator, ADP, as 
well as collagen-induced aggregation, and there is evidence that GP Ilb/IIIa-specific 
monoclonal antibodies can activate platelets via the platelet FcyRIIA receptor (Anderson 
1991; Rubinstein 1991; Bemdt 1993), which suggests that antiplatelet antibodies to this 
glycoprotein complex trigger platelet activation via platelet Fc receptors.
IV-3.2 Anti-GP Ib/IX-V Antibodies
1V-3.2.1 Findings in ITP
Antiplatelet antibodies against the GP Ib-IX complex have been demonstrated in several 
studies (Van Leeuwen 1982; Beardsley 1984; Woods 1984). Around 75% of antiplatelet 
antibodies are known to be against antigens on the GP Ib-IX complex. High levels of plasma 
autoantibodies and platelet-associated antibodies against GP Ib-IX have been found in 
patients with ITP. Tani, (1989) found GP Ib/IX-specific platelet-associated IgG in 80% of the 
ITP patients in their study. (McMillan 1987) detected platelet-associated IgG in ITP patients 
that showed specificity for the GP lb subunit. Furthermore, a class I MHC-associated peptide 
was found on the platelets of ITP patients that correlates with an HLA allele and corresponds 
to the GP lb unit (Hopkins, 2005). GP Ilb/IIIa-specific and GP lb-specific platelet-associated 
IgG antibodies were detected in ITP patients by (Hasegawa 1995).
The GPIb/IX complex is highly immunogenic, with several identified alloantigens and 
epitopes that have been extensively studied (Van Leeuwen 1982; Beardsley 1984; Woods
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1984; Kunicki 1992; Ouwehand 2000). Autoantibodies to GP Ib/IX are known attach only to 
limited regions, and a very specific region on the GP lb subunit.
Some studies indicate that GP lb is the target antigen in autoimmune thrombocytopenia 
(Stiene-Martin 1998; Kahn 1999; Moran 2000) and platelet-associated IgG with specificity 
for the GP lb subunit has been shown in ITP patients (McMillan 1987; Hasegawa 1995). The 
patients in the study by (Hasegawa 1995) were positive for platelet-associated IgG. Other 
proposed targets include the one on the GP lb alpha component, close to the membrane, and 
extracellular epitopes on the GP lb beta component (Joutsi-Korhonen 2000). Further 
associations have been shown in ITP patients with the B7 allele of the HLA system that 
relates to GP lb (Hopkins 2005).
Three separate studies (Tani 1989; Kiefel 1996; Hurlimann-Forster 1997) demonstrated 
antibodies specific for GP Ib/IX in patients with ITP. In one of these studies, they were found 
to be platelet-associated IgG antibodies (Tani 1989).
IV-3.2.2 Effects of Disruption
GP Ib-IX-V complex forms the vWF receptor. There are approximately 11,000 copies on the 
platelet membrane (Kahn 1999). Through interactions with vWF, thrombin and actin, the 
complex facilitates platelet adhesion to vascular subendothelium after vascular injury, and it is 
involved in processes that lead to platelet activation and thrombus formatioa The GP lb 
component is thought to be involved in the aetiology o f autoimmune thrombocytopenia 
(Stiene-Martin 1998; Kahn 1999; Moran 2000) and its is associated with the impaired
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megakaryocyte production of platelets seen in ITP (Hasegawa 1995). In this study, patients 
with GP lb specific-autoantibodies had normal numbers of megakaryocytes, but they were 
smaller than those found in patients with GP Ilb/IIIa-specific antibodies (Hasegawa 1995). 
Platelet-associated IgG was positive in these patients.
IV-3.3 Anti-GP Ia/IIa Antibodies
IV-3.3.1 Findings in ITP
Circulating antiplatelet antibodies with specificity for the GP Ia/IIa complex have been 
demonstrated, but there is limited evidence for their presence in patients with ITP. One patient 
with a bleeding disorder was shown to have GP Ia/IIa-specific antiplatelet antibodies (Godeau 
2008).
The GP la subunit interacts directly with collagen molecules and platelet aggregation can be 
blocked by anti-GPIa monoclonal antibodies.
GP Ia/IIa interacts with collagen and platelets lacking GP la fail to react properly with 
collagen of this receptor may have an effect on collagen-induced platelet aggregation. Studies 
suggest this receptor is involved in type I collagen-induced platelet spreading and aggregation 
(Monnet 2000).
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IV-4 Other Autoantibodies in ITP
IV-4.1 Autoantibodies to Other Platelet Antigens
In the pathogenesis of ITP, intravascular platelets can form self-antigens from some non­
glycoprotein particles. Antibody targets other than glycoproteins have been found on platelets 
in ITP patients. These are various unidentified proteins and glycolipid, glycosphingolipid and 
phospholipid molecules.
In a meta-analysis, 30% of people with ITP were found to have antiphospholipid antibodies. 
Circulating antibodies against various internal platelet proteins, such as vinculin, talin, and 
tropomyosin have also been demonstrated in ITP patients and controls (Tomiyama., 1992). 
These proteins are all components of the cytoskeleton. However, they are not expressed on 
the surface of normal platelets, and are only detected in the sera of ITP patients following 
lytic destruction of platelet, when they are exposed and become autoantigenic (Wadenvik 
1998).
Another antigenic target among ITP patients is a platelet granule membrane glycoprotein of 
140 kDa, GMP-140. This protein translocates from the secretory granules of platelets and 
endothelium to the surface after activation (Bierling 1994).
Other antigens on the surface of a platelet may evoke production of antibodies. These include 
the human leukocyte antigens (HLAs) and the A and B antigens of the ABO blood-typing 
system These ABO antigens are associated with transfusion reactions and transfusion- 
induced thrombocytopenia.
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The HLA system relates to the cell-surface antigen-presenting proteins of the MHC in 
humans. The system is important in the immune response generally and in the pathogenesis of 
certain autoimmune diseases (Janeway 1999). There are MHC molecules on approximately 
73% of platelets in humans (George 1985; Taaning 1992; Daci 1995), normally class I MHC 
molecules. MHC class I-associated peptides are present on the platelets of healthy people and 
patients with ITP (Hopkins 2005). Most studies on ITP patients show no change in the 
frequency of HLA class IA, IB or IC antigens (McMillan 1980; Gaiger 1994).
Human platelet antigens (HPAs) are found within the glycoprotein complexes. They can 
trigger production of platelet-specific alloantibodies against donor antigens. Platelet HP As 
include HPA-1, HPA-2, HPA-3, HPA-4, HPA-5, HPA-6, HPA-7, HPA-8, HPA-9, HPA-10, 
Ly®, Sit8, -Groa and -Oea
IV-4.2 Autoantibodies to Other Cells
There is experimental evidence of binding of autoantibodies to megakaryocytes in chronic 
ITP patients (McMillan 1978; Hoffman 1985). . These in vitro studies showed that IgG- 
specific autoantibodies produced by ITP patients bind to megakaryocyte-associated antigens 
on the precursors. Autoimmune reactions against megakaryocytes, which are associated with 
platelet dysfunction, arise because the megakaryocytes carry the same antigens as mature 
platelets on their surface, which antiplatelet antibodies may interact with. Ultimately this 
disrupts megakaryocyte colony formation and platelet development (McMillan 1978;
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Hoffman 1985). The impaired megakaryocyte production of platelets in ITP occurs in 
approximately 20% of patients with ITP (Ballem 1987) and it is thought to depend on 
autoantibodies against the glycoprotein GP lb (Hasegawa 1995). ITP patients with circulating 
GP Ib-specific autoantibodies had normal numbers of megakaryocytes, but these were smaller 
in size than those found in patients with GP Ilb/IIIa-specific antibodies (Hasegawa 1995).
1V-5 Platelet-Specific Immunoglobulins in ITP
Around 80% of chronic ITP patients have antiplatelet antibodies o f the immunoglobulin 
classes IgG, IgA and IgM against epitopes of glycoproteins on the external membrane of 
platelets (He 1994). IgM and IgA levels tend to be higher in people with acute ITP, and IgM 
and IgA and IgG tends to be higher in the chronic form Antiplatelet antibodies of all three 
immunoglobulin classes have been reported to correlate with the platelet count (Kokawa 
1991; Movahed Shariat Panahi 1994) and therefore they would all be expected to have a role 
in the pathogenesis of ITP. However, IgM and IgA antiplatelet specific antibodies do not 
contribute greatly to thrombocytopenia caused by increased platelet destruction, which is the 
mechanism involved in ITP. (Kiefel 1996) detected glycoprotein-specific platelet-associated 
immunoglobulins in patients with autoimmune-mediated thrombocytopenia -  46% were IgG 
specific, 15% were IgM specific and 3% were IgA specific. In another study, platelet- 
associated IgG was found in 92% of patients with ITP, IgM was found in 42% and IgA in 9% 
(van der Schoot 1986).
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IV-5.1 Platelet-Associated IgG
Numerous autoantibodies with different specificities are found in an individual ITP patient. 
About a quarter of the autoantibodies produced by ITP patients are against different 
membrane glycoproteins or glycolipids, and the serum of 80% of chronic ITP patients 
contains platelet-specific immunoglobulins of various kinds. About 90% of the autoantibodies 
are known to be o f the IgG immunoglobulin type (McMillan 1974; Schwartz 2007) and they 
can be detected in about 60% of ITP patients (Coopamah 2003). Platelet-associated IgG has 
been detected on the platelet membrane in 75-90% of patients with ITP (McMillan 1987; 
Berchtold 1993). The main isotype is IgG (Wadenvik 1998; Winiarski 1998) and splenic IgG 
production has been shown to be increased in patients with ITP (McMillan 1974).
Unfortunately, the presence of platelet-associated IgG is not specific for ITP (Mueller- 
Eckhardt ,1980). It is also found in patients with thrombocytopenia from non-immune causes 
(Helmerhorst 1982) and in patients with other systemic blood diseases. In one particular 
study, platelet-associated IgG was found in 78% patients with ITP and in 81% patients with 
non-immune thrombocytopenia (Warner, 1999). Other studies have shown glycoprotein- 
specific platelet-associated IgG in 46% of patients with autoimmune-mediated 
thrombocytopenia (Kiefel 1996) and 92% of patients with ITP (van der Schoot 1986).
Measurement of platelet-associated IgG is complicated due to naturally occurring antibodies, 
internal platelet IgG and aggregated IgG in immune complexes bound to platelets (Rosenfeld 
1985; Muniz-Diaz 1995). Normal platelets contain approximately 5 femtograms of IgG, of 
which only about 1% occurs on the platelet surface. Most is contained within the platelets,
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within the alpha granules (Leissinger 1992) and this is mostly IgGl and IgG3 (Taaning 1988). 
The amount of platelet-associated IgG is inversely proportional to platelet count and to the 
mean platelet lifespan (Panzer 1986). In ITP patients, any increase correlates with a reduced 
platelet count. However, antiplatelet antibodies may be present even if the platelet count is 
normal.
Antiplatelet IgG has been shown to fix the complement protein C3 to platelets, and this ability 
to fix complement influences in part the severity of thrombocytopenia (McMillan 2000).
IV-5.2 Glycoprotein-Specific Platelet-Associated IgG
IgG-specific antiplatelet antibodies are directed against various glycoprotein receptors in the 
platelet membrane (Schwartz 2007). (McMillan 1987) demonstrated glycoprotein-specific 
platelet-associated IgG in 75% of patients with ITP. (Tani 1989) detected glycoprotein- 
specific specific platelet-associated IgG in 80% of patients with ITP.
Most of these specific autoantibodies are produced against the highly immunogenic 
glycoprotein complexes GP Ilb/IIIa (Yanabu 1991) and GP Ib-IX (Van Leeuwen 1982; 
Beardsley 1984; Woods 1984). The major autoantigens are found on the GP Ilb/IIIa complex 
(Yanabu 1991), with anti-GP Ilb/IIIa autoantibodies occurring in approximately 15% of ITP 
patients. These antibodies react with the carboxy-terminal region of GP Ilia, which is located 
within its cytoplasmic region, as well as targetting epitopes in other areas (McMillan 2000). 
GP Ilb/IIIa-specific platelet-associated IgG in samples from thrombocytopenic patients 
(Warner 1997).
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Platelet-associated IgG can be detected using a range of analytical methods, such as 
immunobead, MAIPA and MACE. Improving the detection of glycoprotein specificity will 
improve the accuracy of tests for detecting and classifying thrombocytopenia that has an 
autoimmune basis. Detection of glycoprotein-specific platelet-associated IgG also improves 
our understanding of the nature of antiplatelet antibodies in the different types o f 
thrombocytopenia. For example, GP Ilb/IIIa- and Gp Ib/IX-specific platelet-associated IgG 
was detected in 49% of patients with ITP and in 22% of patients with non-immune 
thrombocytopenia by (Brighton 1996)., and GP Ilb/IIIa-specific platelet-associated IgG was 
detected in 39% of patients with ITP and some with non-immune thrombocytopenia by 
(Warner 1997).
Binding of anti-IgG autoantibody on the glycoprotein complexes is highly specific. They 
attach to very specific regions on the GP Ilb/IIIa, GP Ib/IX complexes and the GP lib and 
GP lb subunits (Joutsi-Korhonen 2000). The autoepitopes recognised by circulating 
antibodies are a 65-kDa site on the carboxy terminal and amino acids 23-38 on GP nib 
(alpha). On GP Ilia, autoantibodies bind to a 33 kD-cysteine-rich site, the cytoplasmic 
carboxy terminal, a region at amino acids 39-73, and the Ilb/IIIa complex. In one ITP patient, 
there was binding to amino acids 35-50 of GP Ilia (Joutsi-Korhonen 2000). GP lb alpha 
antibodies bind to close to the membrane and GP lb beta antibodies bind to extracellular 
epitopes.
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IV-6  Aims of the Study
The aim of this study is to recognise autoantibodies against human platelet antigens, 
specifically the glycoprotein complexes targeted in the autoimmune disease ITP, such as 
GP Illa/IIb and GP Ib/Ix, using platelet lysate and whole platelets from healthy volunteers and 
a library of antibody Fab fragments derived from splenic B lymphocytes of a patient with ITP. 
Anti-platelet Fab fragments will be isolated from a phage library (of electrocompetent 
Escherichia coli (K12) and Ml 3 helper phages) by serial biopanning. ELISA will be used to 
identify the glycoproteins, and dot blotting and western blotting techniques will be used to 
further characterise the antigens.
IV-6.1 Objectives
• The isolation of anti- platelet antibodies from an ITP patient by transfection using a 
phage library
• Characterisation of the isolated antibodies through ELISA, and blotting assays.
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II -  MATERIALS AND METHODS
II—1 Preparation of Washed Whole Platelets 
Materials
• Anti-coagulant, acid citrate dextrose (ACD) -  100 mM sodium citrate, 40 mM citric acid, 
140 mM dextrose in distilled water
• Isotonic buffer -  10 mM Tris base, 150 mM sodium chloride (NaCl), 1 mM ethylenediamine 
tetra-acetic acid (EDTA), pH 7.4
• Isotonic citrate buffer -  50 mM sodium citrate, 100 mM NaCl, 140 mM glucose, pH 6.2 
Method
60 ml anti-coagulated (ACD) blood, prepared from healthy volunteer (PhD student) was 
centrifuged at 200 g  for 20 minutes at room temperature (15-22 0 C). After which the platelet 
rich plasma (PRP) was removed. 1 pg/ml diluted prostaglandin (1 in 4 in ethanol) was added 
and the PRP re-centrifuged at 1200 g for 12 minutes. After washing the sedimented platelets 
four times with isotonic citrate buffer, the platelets were resuspended in 1 ml isotonic buffer 
containing 10% dimethylethyl sulfoxide (DMSO) and aliquoted at a concentration o f 109 ml' 1 
and stored at -20 °C. The thawed platelets were washed with isotonic citrate buffer before 
use.
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II—2 Preparation of Platelet Lysate
Materials
• Lysis buffer -  20 mM Tris, 150 mM NaCl, 1 mM MgCl2, 1 mM CaCl2, pH 7.4, 0.004 mM 
phenylmethanesulfonylfluoride (PMSF), 1% Triton X 100
• Phosphate-buffered saline (PBS) -lOOmM sodium hydrogen phosphate (NaHP04), 
150 mM NaCl, 30 mM EDTA, pH 7.4
All standard laboratory regents and chemical were supplied by the Sigma Company Ltd and 
BDH (Merck Ltd) in the UK.
Method
Purified whole platelets were prepared as described before (see II. 1). Then 6 ml lysis buffer 
was added and incubated at 4 °C for 1 hour, after which the lysate was centrifuged at 20,000 g  
for 30 minutes at 4 °C. The supernatant was aliquoted into 0.5 ml tubes and stored at -20 °C.
II—3 Concentration of Lysate Protein
5 ml o f the supernatant was concentrated using a centrifugal filter device (10,000 MW cut­
off) at 4,000 g  for 40 minutes. The concentrated platelet proteins were aliquoted into 500-p.l 
Eppendorf tubes and stored at -20 °C.
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II—4 Determination of Platelet Protein Concentration
The Bio-Rad DC protein assay is a colourimetric assay for determining protein concentration 
following detergent solubilisation. The assay is based on the reaction of protein with an 
alkaline copper tartrate solution and Folin reagent. The amino acids tyrosine, tryptophan, 
cysteine, and histidine affect the reduction of the Folin reagent by the loss of 1, 2 or 3 oxygen 
atoms. This produces one or more of several possible reduced species with a characteristic 
blue colour with maximum absorbance at 750 nm.
Materials
• DC Protein Assay Kits (Bio-Rad Laboratories) including:
Reagent A -  An alkaline copper tartarate solution 
Reagent B -  Folin solution
Reagent S -  For samples that used a surfactant reagents such as Triton X-100
• Standard bovine serum albumin(BSA)
Method
BSA at an initial concentration o f 1.6 mg/ml was used to produce a standard curve by serial 
dilution. A standard concentration range (100 pg/ml, 200 pg/ml, 400 pg/ml, 600 pg/ml, 
800 pg/ml, 1200 pg/mll400 pg/ml, 1600 pg/ml) was prepared with isotonic buffer and two 
undiluted samples and two samples diluted 1 in 10 with lysis buffer. Working reagent A was
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prepared by adding 20 pi of reagent S to 1 ml reagent A. Then 5 pi o f each standard and 
sample along with 5 pi of buffer as a blank and 25 pi of reagent A were added to separate 
wells o f an ELISA microplate (Maxisorb™).
The plate was shaken carefully. Then 200 pi o f reagent B was added to each well and mixed 
immediately. The plate was left at room temperature for 15 minutes after which the 
absorbance at 750 nm was read with an ELISA plate reader (MRXII Dynex Technologies).
II-5 ELISA Detection of Platelet Membrane Glycoproteins 
Materials
• Monoclonal antibodies anti human CD41 (GP Ilb/IIIa) and anti human CD-61 (GP Ilia) 
(Novacastra Company Ltd)
• Rabbit anti-mouse IgG horseradish peroxidase (HRP) conjugated antibody (Sigma Chemical 
Company)
• Coating buffer -  1M sodium hydrogen carbonate, pH 8.3
• Washing buffer -  0.05% Tween-20 in PBS
• Substrate solution -  one 10 mg tablet o-phenylenediamine dihydrochloride (OPD) dissolved 
in 25 ml citrate buffer with 10 pi of 30% H2O2 (OPD and H2O2 obtained from the Sigma 
Chemical Company)
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Method
Microtitre plate wells were coated with 100 pi of platelet lysate (200 pg/ml) or 100 pi 
containing 107 washed whole platelets and incubated at 4 °C overnight. After washing twice 
with 250 pi PBS-Tween 20, the plates were blocked with 200 pi o f 5% dried milk in PBS and 
left for 1 hour at room temperature. After two further washes with PBS-Tween 20, 50 pi of 
mouse monoclonal anti- Ilia (CD61) or anti- Illa/IIb (CD41), diluted 1 in 100 with 5% dried 
milk in PBS, was added and incubated for 2 hours at 37 °C.
The plate was washed a further six times with PBS-Tween 20. Then 50 pi o f a 1 in 1000 
dilution of rabbit anti-mouse IgG HRP-conjugated antibody in 5% dried milk in PBS was 
added to each well. The plate was incubated for 1 hour at 37 °C. After another six washes 
with PBS-Tween 20, 200 pi OPD substrate buffer was added to each well. The plate was 
covered with foil and incubated for 30 minutes at room temperature. The absorbance was read 
at 450 nm.
1 -6  Titration of Anti-Glycoprotein Antibodies
100 pi diluted monoclonal antibody against CD41 over the range 1.0 * 10~2 to 6.25 x 10"* 
pg/ml was added to the well o f a microtitre plate and incubated overnight at 4 °C. The 
following morning the plate was washed twice with wash buffer PBS-Tween 20 and blocked 
with 5% dried milk in PBS for 2 hours at 37 °C. The plate was washed once, as above. 100 pi
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of washed platelets containing 107 platelets was added to each well and incubated for 2 hours 
at 37 °C in a carbon dioxide incubator.
The anti-platelet antibodies were detected by the addition of 100 pi rabbit anti-mouse IgG 
HRP-conjugated antibodies diluted 1 in 1000 with 5% dried milk in PBS. The plate was then 
incubated for 2 hours at 37 °C. After six more washes, 200 pi OPD substrate was added to 
each well and left at room temperature for 30 minutes. The absorbance was read at 490 nm.
II-7 Titration of Platelet glycoprotein(CD-41 and CD-61)
100 pi of whole platelet suspension over the range 107—104 platelets per well or 100 pi platelet 
lysate concentration over the range 600-1 OOg/ml was added to a microtitre plate and 
incubated at 4 °C overnight. The following morning the plates were washed twice with PBS- 
Tween 20, blocked with 5% dried milk in PBS and left for 2 hours at 37 °C. Then 100 pi of 
mouse anti-CD61 or anti-CD41 at a concentration of 5 pg/ml (diluted with 5% dried milk in 
PBS) was added and incubated for 2 hours at 37 °C. After six washes with wash buffer, 
100 pi of rabbit anti-mouse IgG HRP-conjugated antibody, diluted 1 in 1000 (with 5% dried 
milk in PBS )was added to each well and incubated for 2 horns at 37 °C. The plates were 
washed more six times and 200 pi OPD substrate buffer was added to each well. After 
30 minutes incubation at room temperature the absorbance was read at 490 nm.
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II—8 Preparation of Electrocompetent E sch erich ia  co li (K12)
Materials
• Luria broth (LB) 1 L -  10 g tryptone, 5 g yeast extract, 10 g NaCl, made up to 1 L in
distilled water, pH 7.0 (adjusted with NaOH)
• LB agar -  1 L of Luria broth, 10 g bacteriological agar
• Super broth (SB) 1 L -  10 g 3-(Ar-morpholino) propanesulfonic acid (MOPS), 20 g yeast
extract, 30 g tryptone ,made up to 1 L in distilled water, pH 7.0 (adjusted with NaOH)
Method
2 pi of Escherichia coli (K12) from a glycerol stock was cultured on a dry, warm Luria media 
agar plate and incubated at 37 °C for 24 hours. A single colony was inoculated into 10 ml SB 
with 15 mg/ml tetracycline and incubated overnight at 37 °C at 200 r.p.m. in an orbital shaker. 
Then 2.5 ml o f the overnight culture o f Escherichia coli (K12) suspension was transferred 
into 500 ml SB with 10 ml 20% (w/v) glucose and 5 ml MgCk, without any antibiotic. The 
culture was incubated at 37 °C on an orbital shaker until the OD at 600 nm reached 0.7-0.8. 
After chilling the culture on ice for 15 minutes, it was centrifuged at 3,000 g  for 20 minutes at 
4 °C. The supernatant was then discarded and the cells resuspended in 250 ml chilled wash 
buffer containing 10% glycerol, and centrifuged at 3000 g  for 20 minutes. The supernatant 
was poured off and the washing step was repeated. Then the supernatant was discarded and 
the cells were resuspended in 12 ml 10% glycerol and transferred to a chilled 500-ml tube.
Page | 102
This sample was centrifuged at 2,300 g  for 15 minutes at 4 °C. The supernatant was carefully 
poured off and the cells were resuspended in 3 ml of the wash buffer. The cells were 
dispensed immediately into 0.5-ml tubes and stored at -80 °C.
II-9 M13 Helper Phage
II-9.1 Preparation of M13 Helper Phage
A colony o f Escherichia coli (K12) was transferred from LB agar containing 15 pg/ml 
tetracycline to 10 ml LB broth with supplements (1% 1 M MgSC>4 and 0.3% 2 M maltose) and 
was shaken at 200 r.p.m. at 37 °C. After the optical density (OD) at 600 nm reached 0.3, the 
commercial helper phage (VCSM13; Stratagene) was added at a multiplicity o f infection of 
20 to 1 (phage to cell ratio) and was incubated at 37 °C for 15 minutes. Shaking was 
continued at 37 °C for 30 minutes. Then 25 pg/ml kanamycin was added and the shaking 
continued for another 7.5 hours. The culture was heated at 65 °C for 15 min in hot water 
before being centrifuged at 2,300 g  for 15 minutes. The supernatant was kept at 4 °C.
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II—9.2 Titration of Helper Phage
Materials
• NZY agar -  5 g NaCl, 2 g MgSC>4 (7 H20), 5 g yeast extract, 10 g NZ amine, 15 g agar,
made up to 1 L in distilled water, pH 7.5 (adjusted with NaOH)
• NZY top agar -  1 L NZY broth, 0.7% (w/v) agar
• SM buffer -  5.8 g NaCl, 2.0 g MgS04, 50 ml 1 M Tris-HCl (pH 7.5), 5 ml 2% (w/v) 
gelatin, made up to 1 L in distilled water
Method
A colony o f isolated Escherichia coli (K12) (on a tetracycline plate) was transferred into 
10 ml LB broth with supplements in a 50-ml conical tube and incubated at 37 °C with 
shaking, until an OD 600 nm of 1.0 was reached. A serial dilution of the bacteriophage in SM 
buffer to create lO'6, 10‘7 and 10'8 dilutions of the phage was prepared. 1 pi of each dilution 
was added to 200 pi of the K12 culture. After incubating the samples for 15 minutes at 37 °C, 
3 ml NZY top agar, melted and cooled to 48 °C, was added to the samples, then plated onto 
dry and pre-warmed NZY agar plates and left to set before being inverted and incubated 
overnight at 37 °C. The count o f phage in the plate was calculated from following equation:
Number of plaques (p.f.u.) x dilution factor
Count/ml =__________________________________ _____ x 1000
Volume plated (pi)
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II—10 DNA Isolation
Alkaline lysis releases plasmid DNA from bacteria and ribonuclease A (RNase A) removes all 
the RNA in the lysate. In the presence of the chaotropic salt, guanidine hydrochloride, 
plasmid DNA binds selectively to special glass fibres pre-packed in the HighPure™ filter 
tube. Bound plasmid DNA is purified in a series of rapid "wash and spin" steps to remove 
contaminating bacterial components. Low salt elution then releases the DNA from the glass 
fibre. This eliminates the need for organic solvent extractions and DNA precipitation, 
allowing for rapid purification of many samples simultaneously.
II—10-1 DNA Preparation
Materials
• HighPure™ plasmid isolation kit available from Roche, with 50 HighPure™ filter tubes
(polypropylene tubes with two layers of glass fibre)
• Suspension buffer -  0.05 M Tris-HCl and 0.01 M EDTA, pH 8 (25 °C)
• RNAse A
• Lysis solution -  0.2 M NaOH, 1% sodium dodecyl sulphate (SDS)
• Binding buffer -  4 M guanidine hydrochloride, 0.05 M potassium acetate, pH 4.2
• Wash buffer I -5  M guanidine hydrochloride, 20 mM Tris-HCl, pH 6.6, 75% (v/v) ethanol
• Wash buffer II -  40 ml 0.02 M NaCl, 0.02 M Tris-HCl, pH 7.5
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• Elution buffer — 0.01 M Tris-HCl, pH 8.5 
Method
100 pi of electrocompetent Escherichia coli cells (K12) were inoculated into a pre-chilled 
tube with 5 pi of plasmid DNA (from a phage library containing DNA of the heavy chain 
domains VH and CHI, and light chain domains VL and CL, of the antibodies in PAK100 
vector, constructed using mRNA obtained from splenic lymphocytes of one patient with 
idiopathic thrombocytopenic purpura (ITP) and systemic lupus erythematosus (the phage 
library was a gift from Dr Lynda Partridge at the University of Sheffield).
The sample was left in ice for 2 minutes. Then it was transferred into a pre-chilled 
electroporation cuvette. A 5-second pulse o f 2.5 kV was applied to the sample by a gene 
pulser (BioRad). Immediately 1 ml SB was added to the cuvette and the contents were 
transferred to a 15 ml tube. After shaking for 1 hour at 37 °C and 200 r.p.m, 200 pi of the 
culture was inoculated into 10 ml SB containing chloramphenicol (25 pg/ml) and shaken 
overnight at 37 °C and 200 r.p.m The following day the sample was centrifuged at 3000 g  at 
room temperature for 15 minutes and the supernatant was discarded. The pellet was treated 
with a QLA-Prep Spin MiniPrep kit which was designed for the purification of 20 pg of high- 
copy plasmid DNA.
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II—10.2 DNA Loading on Agarose Gel
A 1% agarose gel in TAE buffer (10  mM Tris, 1 mM EDTA) was prepared and left at room 
temperature for 30 minutes. After this time, 5 pi o f the sample, which was diluted with 
loading buffer( bromophenol blue), 4 ml DNA to 1 ml'loading buffer, and 5 pi of DNA 
marker were inoculated in separate wells. The gel was run at a constant voltage of 100 volts 
for approximately 40 minutes at room temperature. After running, the gel was visualised and 
photographed using the UVI Save Imaging System (UVItec Company).
II-10.3 Restriction Enzyme Digestion of DNA 
Materials
• Elution buffer -  0.01 M Tris-HCl, pH 8.5
• Restriction enzymes — BstXI, Xhol XI, Xbal, SacI, Nehl (Boehringer Mannheim)
• Buffer H -  (Boehringer Mannheim)
• Buffer A -  (Boehringer Mannheim)
• Buffer M -  (Boehringer Mannheim)
• Deionised water
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Method
To confirm whether the DNA of the heavy and light chains had been inserted into the plasmid 
DNA, the DNA was cut with restriction enzymes to isolate the insertion. For each sample, 
three Eppendorf tubes were prepared: one for the heavy chain digest, one for the light chain 
digest, and one for the undigested DNA. Then 25 pi DNA was added to each tube, along with 
2 pi o f the restriction enzymes.BstXI (10 U/pl) and Xhol XI (10 U/pl) were used for the 
heavy chain, 2 pi o f Xbal (10 U/pl) and 2 pi SacI (10 U pl-1) were used for the light chain, 
and 2 pi of Nehl (10 U/pl) was used for the undigested sample.
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11-11 Biopanning
II—11.1 Transfection and Amplification of E scherich ia  co li (K12) by library Phage
50 pi o f electrocompetent cells (K12) were placed in a pre-chilled tube with 5 pi plasmid 
DNA from phage library that contained DNA of the heavy chain (VH and CHI) and light 
chain (VL and CL) domains o f the antibodies. The solution was left on ice for 2 minutes. 
Then an electric pulse of 2.5 kV was applied by gene pulser for 5 seconds. The solution was 
washed immediately with LB and transferred to a 50 ml tube. Then 4 ml LB was added and 
the sample was shaken for 1 hour at 37 °C and 200 r.p.m. after which 10 ml LB containing 
25 pg/ml chloramphenicol and 15 pg/ml tetracycline was added to the solution. To check the 
success of transfection, aliquots of 1 pi, 10 pi and 100 pi of the diluted culture (1 in 100) were 
plated onto LB agar containing 25 pg/ml chloramphenicol and incubated at 37 °C for 
24 hours. Then 5 pi of 25 pg/ml chloramphenicol was added to the sample and shaken for 
1 hour. On completion, 2 ml VCSM (helper phage) was added and left for 15 minutes at room 
temperature. Then 200 ml LB containing 15 pg/ml tetracycline and 25 pg/ml chloramphenicol 
was added and shaken at 200 r.p.m. for another 2 hours. The solution was then mixed with 
70 pg/ml kanamycin and shaken overnight.
The next day, the suspension was centrifuged at 3000 g  at 4°C for 15 minutes. The 
supernatant was transferred to a clean sterile bottle containing 4% (w/v) PEG-8000 and 3% 
(w/v) NaCl and placed on ice for 30 minutes. It was centrifuged at 15,000 g  for 20 minutes at 
4 °C. The supernatant was discarded, and a paper towel was used to remove as much PEG-
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8000 solution as possible. The pellet was resuspended in 2 ml 1% BSA and centrifuged for 5 
minutes at 13,000 g. The supernatant was stored at 4 °C.
II—11.2 Panning of Platelet Binding Phage
Materials
• Coating buffer- 1M Bicarbonate buffer, pH 8.3
• Washing buffer- PBS-Tween 20 (0.05%)
• Acidic elution buffer-100 mM glycine- HC1, pH2.2
• Neutralisation solution - 2 mM Tris base 
Methods
An ELISA plate was coated with 100 pi of the platelet suspension containing 108 platelets in 
bicarbonate buffer (pH 8.6) and incubated overnight at 4 °C. The plate was washed twice with 
PBS and blocked with 200 pi of 5% dried milk in PBS. Then it was incubated for 1 hour at 
37 °C. After two more washes with washing buffer, 50 pi of the phage suspension (from 10.1) 
was added to each well and the plate incubated for 2 hours at 37 °C. The excess phage was 
removed by discarding the liquid phase. The wells were filled with PBS-Tween 20 (0.05%) 
and pipetted vigorously. After 5 minutes the PBS-Tween 20 was removed. For the first round 
of panning, the plate was washed once, with PBS-Tween 20. The next four rounds of panning 
involved five washes.
Page | 110
The phage was eluted by adding 50 pi o f acidic elution buffer per well. After leaving at room 
temperature for 10 minutes it was pipetted vigorously. Then the eluted phage was removed 
and neutralised with 3 pi neutralisation solution (2 M Tris base).
II—11.3 Library Phage Replication and Re-Amplification
The solution obtained from the last round of panning was inoculated with 10 ml LB 
containing 2 pi Escherichia coli (K12) and 15 pg/ml tetracycline. This was shaken at 
200 r.p.m. at 37 °C. Optical density was continuously checked at 600 nm. Shaking was 
discontinued when an OD of 1 was obtained. The phage was added to the culture and left for 
15 minutes at room temperature. After that time, 25 pg/ml chloramphenicol was added and 
the solution was transferred to 200 ml LB. Shaking continued for another 1 hours. To titre the 
phage-infected bacteria, 1 pi and 10 pi of the diluted culture (1 in 100) was plated onto LB 
agar containing 25 pg/ml chloramphenicol. This was incubated at 37 °C overnight.
Subsequently, 2 ml VCSM (helper phage) was mixed with the solution and incubated for 15 
minutes at room temperature. Then 25 pg/ml chloramphenicol and 15 pg/ml tetracycline were 
added and shaking was carried out for 2 hours. After this time, 70 pg/ml kanamycin was 
added, then shaking was continued overnight at 200 r.p.m and 37 °C.
The following day, the solution was centrifuged at 3000 g  and 4 °C for 15 minutes. The 
supernatant was transferred to a clean 500-ml centrifuge tube containing 4% (w/v) PEG-8000 
and 3% (w/v) NaCl. The solution was incubated on ice for 30 minutes and the supernatant
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was discarded after centrifugation at 15000 g  and 4 °C for 15 minutes. The bottle was drained 
by inverting it onto a paper towel for at least 10 minutes.
The phage-plate was resuspended in 2 ml 1% (w/v) BSA in PBS and transferred to a 
microcentrifuge tube. The suspension was centrifuged at 15,000 g  for 5 minutes. Five rounds 
of panning were carried out as before. The eluted phage was titred by infecting 100 pi of 
Escherichia coli, K12, (OD 0.6 at 600 nm) with 1 pi of 10"4, 10-6, 10‘8 and 10'9 diluted phage 
with LB broth) for 15 minutes at room temperature. Each dilution was next cultured on an LB 
plate containing 25 pg/ml chloramphenicol and incubated at 37 °C for 48 hours.
II—11.4 Isolating the Individual Phage from the Phage Pool
After five rounds of panning, the individual colonies isolated from the phage pool were 
examined for reactivity with platelet proteins using the whole-platelet ELISA technique. Each 
random colony from the last round of panning was inoculated in 2 ml LB containing 25 pg/ml 
chloramphenicol and was shaken at 200 r.p.m, and 37 °C. The optical density was 
continuously checked at 600 nm, Shaking was discontinued as soon as the OD reached 1.0. 
Then 0.5 mM IPTG was added to each tube before shaking was carried out overnight at 
200 r.p.m. and 37 °C. The following day, the solutions were centrifuged at 2800 g  and 4 °C 
for 15 minutes. The supernatants were transferred to a clean tube and stored at -20 °C.
Page | 112
11-12 Protein Blotting
Protein blotting involves immobilising proteins on membranes before detection using 
monoclonal or polyclonal antibodies. Enhanced chemiluminescence (ECL) is used in this 
method. ECL is a common technique for a variety of detection assays for detecting the 
horseradish peroxidise (HRP) enzyme, which is tethered to the molecule of interest usually 
through labelling an immunoglobulin that specifically recognises the molecule.
There tire different blotting protocols such as dot blotting and western blotting (Burnette, 
1981, Towbin, 1979).
II-12.1 Dot Blotting of Platelet Proteins
Protein detection using the dot blotting protocol is similar to western blotting in that both 
methods allow for the identification and analysis of proteins of interest. Dot blotting 
methodology differs from western blotting techniques in that the electrophoresis separation in 
not performed. Sample proteins are instead spotted onto membranes and hybridised with an 
antibody probe. Semiquantitative measurements can be made o f the spots. It can identify the 
presence o f a target protein molecule, but gives no information about its molecular weight or 
other properties.. If other molecules of are detected, they will still appear as a single dot.
Materials
• Luminol stock -  250 mM (0.886 g) of himinol in 20 ml dimethylsulfoxide (DMSO) (Sigma 
Chemical Company)
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P-coumaric acid stock -  90 mM of coumaric acid in dimethylsulfoxide.
• Solution 1- 1 ml luminal stock, 0.44 ml P-coumaric acid stock, 10 ml 1 M Tris base at 
pH 8.5 made up to 100 ml with distilled water.
• Solution 2- 64 ml o f 30% H20 2, 10 ml 1 M Tris base (pH 8.5) made up to 100 ml with
distilled water
• Final solution -  1 to 1 mixture of solutions 1 and 2
• Coomassie blue stain -  125 ml distilled water, 25 ml glacial acetic acid, 0.1% (w/v) 
Coomassie Blue, made up to 250 ml with 100 ml methanol, and filtered before used.
• Substrate solution buffer (phosphate citrate buffer) — 25.7 ml (200 mmol) sodium 
dihydrogen phosphate, 24.3 ml (100 mmol) citric acid, in 50 ml deionised water, adjusted 
to pH 5.
• Substrate solution -  one 10 mg tablet o-phenylenediamine hydrochloride (OPD) dissolved in
25 ml citrate buffer, 10 pi 30% H20 2 (OPD and H20 2 from Sigma Chemical Company)
• Stop solution — 3M HC1
Methods
2 pi o f platelet lysate was pipetted onto a membrane and left to air dry. The membrane was
incubated in 5% dried milk in PBS at room temperature and shaken or rotated for 1 hour. The
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blocking solution was removed and the membrane was incubated with the phage as a primary 
antibody and shaken for 2 hours at room temperature. The solution was washed with 0.05% 
PBS-T three times, each for 10 minutes, and was incubated with HRP-conjugated anti-M13 
antibody diluted 1 in 1000 in blocking solution for 1 hour. The sample was washed as same 
above. The blot was developed with 2 ml ECL solution, then washed and placed in a case 
together with a sheet of photographic film and sealed carefully. The film was placed into 
developer until blotting dots appeared, at which point it was immersed in water for 
30 seconds, and placed into FC40 fixative solution until the bands became clear. If no dots 
appeared that means there is none of the target protein present in the sample.
II-12.2 Western blotting of Platelet Proteins
Western blotting is a molecular method to detect protein in a given sample of tissue or 
extract. It uses gel electrophoresis to separate denatured proteins by mass. The proteins are 
transferred out of the gel and onto a membrane, where they are probed using antibodies 
specific to the protein. As a result, western blotting can determine the molecular weight of the 
protein by comparing the movement of the protein on the gel with that of the specified 
proteins. It can examine the number o f proteins in a given sample determine the molecular 
weight of those protein by comparing several bands o f the molecular weight marker 
(Burnette, 1981, Renart, 1979).
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Materials
• Buffer 1 -  1.5 M Tris base, 0.4% (w/v) SDS dissolved 1 in 10 in distilled water, pH 8.4.
• Buffer 2 -  0.5 M Tris base, 0.4% (w/v) SDS dissolved 1 in 10 in distilled water, pH 6.8 .
• Acrylamide gel -  29.2% (w/v) acrylamide gel (Gibco BRL), 0.8% (w/v) bis-acrylamide
(Sigma Company) in 70 ml distilled water and filtered through Whatman paper into a dark 
bottle and stored at 4 °C.
• Resolving gel 8% -  11.5 ml distilled water, 6.5 ml buffer 1, 6.7 ml acrylamide, 15 pi 
tetramethylethylene diamine (TEMED; Sigma Chemical Company), 250 ml Ammonium 
perssulphate (APS )10%
APS -  should be made up fresh each day (100 mg/ml).
• Stacking gel 3% -  4.87 ml distilled water, 1.87 ml buffer 2, 0.75 ml acrylamide, lOpl 
TEMED, 75 pi APS 10%.
• Running buffer -  0.3% Tris base, 1.44% glycine, 1% SDS dissolved in 1 L distilled water.
• Blotting buffer -  0.3% Tris, 1.41% glycine, 20% methanol in 800 ml distilled water
• Working sample buffer
100 ml SDS 20%, 100-ml glycerol, 50 ml TEP, 70 mg Bromophenol Blue (BPB)
Page | 116
For the reducing sample buffer 0.155 g of dithiotheritol (DTT) was added to 20 ml of sample
buffer.
• Reducing sample buffer -  0.155 g dithiotheritol (DTT), 20 ml sample buffer
• Molecular-weight marker (Gibco BRL)
• pure GPIIb/IIIa(Enzyme Research Laboratories,ERL)
Method
The sample was prepared by diluting one part of sample buffer to three parts of either platelet 
lysate protein from section II-2 (200 pg/ml) or pure GPIIb/IIIa (8 pg/ml) and boiling for 
2 minutes.
The resolving gel at 8% was poured and allowed to set. Then the stacking gel was added. 
Then 15 pi o f the protein sample or 5 pi o f molecular weight marker was added to separate 
wells. The gel was run at a constant voltage of 100 volts for 90 minutes.
The protein was transferred from the polyacrylamide gel to a 0.45-pm nitrocellulose 
membrane at 100 volts for 90 minutes. Nitrocellulose membrane strips containing the 
separated platelet proteins were blocked with 5% dried milk protein in PBS for 2 hours at 
room temperature. Then 3 ml of the eluted phage at 106 cfu. (colony forming units) per ml 
was placed onto separate sample strips.
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The negative control was 3 ml of helper phage (Ml 3) at the same concentration (106 cfu per 
ml), and the positive control was 3 ml mouse anti-GPIIIa antibody (1 pg/ml) functioned as the 
positive control. All samples and controls were incubated overnight at 4 °C.
On the following day, the strips were washed with PBS 0.05% Tween-20 for 2 hours. The 
washing buffer was renewed every 20 minutes. Then 3 ml of rabbit anti-M13 phage HRP- 
conjugated antibody was diluted 1 in 1000 with 5% dried milk protein in PBS and added to 
the wells of all the samples. For the positive control, 3 ml anti-mouse conjugated antibody 
diluted 1 in 1000 with 5% dried milk protein in PBS was added.
After incubation at room temperature for 1 hour, the strips were washed as described above. 
The blot was developed with 2 ml ECL solution for 2 minutes, and washed and placed in a 
case along with a sheet of photographic film and sealed carefully for 5 minutes.
The film was placed into 50 ml of CD18 developer solution (Sigma Aldrich Company) 
diluted in 200 ml distilled water, until the blotting bands appeared. When they appeared, the 
film was immersed in water for 30 seconds, then placed into 50 ml FC40 fixative diluted in 
200 ml distilled water until the bands were clear. The film was washed with water and left to 
dry.
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SECTION III: Results
III—1 Combinatorial Library Construction
The use of the polymerase chain reaction (PCR) to produce a large number of identical copies 
of DNA sequences is useful for amplifying the gene segments encoding the V domains of 
antibody(Saiki 1985). The gene to be replicated is inserted into copies of a plasmid containing 
genes that make cells resistant to particular antibiotics and a multiple cloning site. The 
plasmids are then inserted into bacteria by a process called transformation. When the bacteria 
are exposed to particular antibiotics, only the bacteria that take up copies of the plasmid 
survive, because the plasmid makes them resistant. The protecting genes are expressed (used 
to make a protein) and the expressed protein breaks down the antibiotics. In this way the 
antibiotics act as a filter to select only the modified bacteria(Cheng 1994).
These bacteria can be grown in large amounts, then harvested and lysed (often using the 
alkaline lysis method) to isolate the plasmid of interest. Antibody specific for a particular 
antigen can be selected from the library by panning. The phage that binds is recovered and 
amplified through used to infect fresh Escherichia coli.
A  single-chain variable fragment (scFv, 5 x 105> phagemid library o f human immunologlobulin 
light (L) and heavy (H) chains was constructed in this study. The mRNA from the splenic 
lymphocytes of a patient with ITP in the vector PAK 100 was used (Krebber 1997). This 
patient suffered from both SLE and ITP. The phage library was a gift from Dr Lynda 
Partridge from the University of Sheffield. Glycoproteins that recognise the phage can be
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isolated by sequential panning of the library with whole platelets. The phage display system 
enables the production of large quantities of human Fab fragments.
Ill—2 Development of an Assay to Detect Antiplatelet Antibodies and Fab
The purpose of this study was to optimise a simple, quick and sensitive ELISA in order to 
identify and quantify antiplatelet antibodies. The sensitivity of the antiplatelet ELISA 
technique is high. It can detect platelet-specific antibodies even in patients who have high 
levels of multi-specific antibodies.
An ELISA was established to determine the binding of antibody to the platelet glycoprotein 
complexes GP lib (CD41) and GP Ilia (CD61). No reaction was observed with anti-CD61, 
therefore only anti-CD41 was used throughout this study. In order to identify and quantify the 
antiplatelet antibodies, whole washed platelets and frozen platelet lysate were coated on a 
microplate. These cell preparations were obtained from healthy volunteers (PhD students at 
the university).
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Assays were undertaken to establish the most appropriate blocking buffer for use in the 
ELISA and for causing substantial blocking in subsequent experiments. In one experiment, 
100 pi of platelet preparation (the equivalent of 107 whole platelets) in a bicarbonate buffer 
was coated onto an ELISA plate, and then a protein was added to block the remaining binding 
sites on the plate. The effects on the ELISA of three different blocking buffers were 
investigated. These were 5% bovine serum albumin (BSA), 1% BSA, and 5% dried milk in 
PBS.
Fig. III-l shows the results obtained with the three different blocking buffers. All three gave a 
high absorbance for the anti-GP lib antibody (CD41) and good discrimination between the 
sample and the negative control (C.Neg). However, the BSA 5% and dried milk 5% were both 
slightly better at blocking the non-specific binding compared with the BSA 1%, and the dried 
milk 5% was marginally better than the BSA 5%. Therefore, dried milk at 5% in PBS was 
used in all subsequent ELISA assays.
II 1-2.1 Effect of Different Blocking Buffers in the Glycoprotein ELISA
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Figure III—1 Effect of blocking buffer on ELISA detection of human CD-41
1 i
CD41 C.Neg
Figure ffl-1 ELISA results for three different blocking buffers, BSA 5%, BSA 1% and dried 
milk 5% in PBS . Bars represent the anti-CD41 reactivity against CD41 on the membrane 
platelet. Data represent the mean (± SE) absorbance of two experiments. Two wells were used 
for each experiment. The negative control negative (C.Neg) was a 1:1 mixture of PBS and 
milk instead ofanti-CD41.
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Ill—3 Platelet Protein Isolation and Detection
III—3.1 Protein Assay
Platelet lysate was isolated from 60 ml of anti-coagulated normal blood and assayed for 
protein content after concentration with a Centriplus centrifugal filter device with molecular 
weight cut-off of 10 kD. The protein content of the platelet lysate was measured by the 
modified Bradford assay (Bradford 1976). BSA at an initial concentration of 1.6 mg/ml was 
used to produce a standard curve by serial dilution (section II.2).
The standard curve obtained from different dilutions of BSA is shown in Fig. Ill—2. The 
Triton X-100 supernatant contained 1400 pg/ml of platelet protein after concentration. It was 
used to investigate the effect of varying concentrations of platelet lysate in an ELISA assay 
(Fig. Ill—2). The platelet lysate was prepared from the different healthy volunteers, and 
measured, which was used at a concentration of 200 pg/ml in all subsequent experiments 
(section II.4).
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Figure m - 2  Standard curve obtained from different dilutions of BSA protein
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Figure III—2 The standard curve for absorbance BSA protein concentration used to determine 
the protein concentration of the platelet lysate. Two wells were used for each determination.
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To establish the most appropriate concentration of antibody to detect platelet glycoproteins 
with the potential to bind Fab, an ELISA analysis with the monoclonal anti-CD41 antibody 
was performed. In this experiment, 100 pi of platelet preparation containing 107 washed 
platelets was added to each well of an ELISA microtitre plate. After blocking with 5% dried 
milk in PBS, 50 pi of mouse monoclonal anti-CD41 antibody in concentrations over the range 
1.0 x 10"2 to 6.25 x 10"4 pg/ml was added to the plate. Fig. Ill—3 shows that anti-CD41 
antibody gave a high absorbance at the first dilution, but absorbance decreased as the 
concentration decreased. Thus 10'2 pg/ml of anti-CD41 antibody was the optimum 
concentration and this was the concentration used in all subsequent experiments (section II.5).
I l l—3-2 Detection of Platelet Glycoproteins using Different Antibody Concentrations
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Figure III-3 The effect of using different anti-CD41 antibody concentrations for the 
detection of platelet glycoprotein
Figure III-3 Effect of the concentration of monoclonal anti-CD41 antibody on the 
absorbance observed in an ELISA. Data represent the mean (± SE) absorbance of two 
experiments. Two wells were used for each experiment.
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ELISA was performed to identify the optimum concentration of whole platelets to use in 
order to determine potentially Fab-binding platelet glycoproteins. In this experiment, 100 pi 
of whole platelets over a concentration range of 107 to 104 platelets per well was used (section 
II. 5).
Fig. Ill—4 demonstrates the results of an ELISA showing absorbance using varying 
concentrations of whole platelets. The negative control (C.Neg) was a 1:1 mixture of bovine 
serum albumin (BSA) and milk. Data represent the mean (± SE) absorbance of two 
experiments. The results suggested that the maximum reaction between anti-CD41 antiplatelet 
antibody and whole platelets occurred at the maximum concentration of platelets at 108/ml 
(107 platelets per well). It was also observed that the decrease in absorbance was related to a 
decreased number of platelets per well. The maximum reaction occurred at 107 of platelets per 
well, therefore this concentration of platelets was used in all subsequent ELISA assays.
I ll—3.3 Optimum Concentration of Whole Platelets for Use in the ELISA
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Figure III—4 Binding curve for different numbers of whole platelets against anti-
CD41 antibody
Figure III-4 ELISA showing absorbance for different concentrations of whole platelets. The 
negative control (C.Neg) was a 1:1 mixture of bovine serum albumin (BSA) and milk. Data 
represent the mean (± SE) absorbance of two experiments. Two wells were used for each 
experiment.
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ELISA was used to determine the optimum concentration of platelet lysate to be used for 
detecting anti-CD41. In this case, 100 pi of platelet lysate over the concentration range of 
100-800 pg/ml was loaded in each well. Then 100 pi of the anti-CD41 antibody, diluted 1 in 
100 with 5% dried milk in PBS was added. The absorbance was read at 450 nm(section II.5).
Fig. Ill—5 shows the results of this ELISA. In order to plot the graph, the concentration of 
platelet lysate was chosen as the independent variable, represented on the x-axis, and 
absorbance was shown on the y-axis as the dependent variable. It shows that decreasing the 
concentration of platelet lysate per well decreases the amount of binding of anti-CD41 
antibody. The highest concentration of platelet lysate gave the highest absorbance. The 
optimum concentration of platelet lysate was detected at a concentration o f 200 pg/ml which 
it is the same amount of protein of 107 whole platelet per well (Kelton 1983) ,and it is used in 
other studies.
I l l—3.4 Optimum Concentration of Platelet Lysate for Detecting Anti-CD41 Antibody
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Figure III—5 Th e effect of different concentrations of platelet lysate on the binding of
anti-CD41 antibody
Figure III-5 The effect of varying platelet lysate concentration on the binding of anti-CD41 
antibodies, as shown by the absorbance. In order to plot the graph, concentration of platelet 
lysate has been chosen as the independent variable represented on the x-axis and absorbance 
has been shown on the y-axis as the dependent variable. The experiment was performed 
twice, two wells were used for each experiment.
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I ll—3.5 Binding of Antibodies to Platelet CD41 on Whole Platelets and Platelet Lysate
To determine whether the whole platelet preparation or platelet lysate functions better as a 
substrate, for use in future assays, an ELISA analysis of the platelet glycoprotein Ilb/IIIa 
complex was undertaken using anti-CD41 antibodies.
Fig. Ill—6 shows the ELISA analysis of anti-CD41 antibody reactions to 107 whole platelets 
per well and 100 pi per well of platelet membrane lysate at a concentration of 200 pg/ml, it is 
the same amount of protein of 107 whole platelets per well (Kelton 1983). There was a 
significant reaction of the antibody against CD41 in the platelet lysate preparation, with an 
even stronger reaction occurring in the whole platelet reaction.
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Figure III—6 A comparison of the binding of antibodies to platelet CD41 on whole 
platelets and platelet lysate
Figure III-6 ELISA comparing the binding of monoclonal anti-CD41 to whole platelets and 
platelet lysate. Data represent the mean (± SE) absorbance of two experiments. Two wells 
were used for each experiment. Blocking buffer (5% dried milk in PBS) was used as a blank 
for control.
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Ill—4 Isolation of Antiplatelet Fab Fragments
The Fab library was constructed at the University of Sheffield from the splenic 
B lymphocytes of a patient with ITP. Phage-recognising platelet antigens were isolated. The 
phage was added to 100 pi of 107 whole platelet coated to each well of an ELISA plate and 
left to attach to the platelets. Then the attached phage was eluted and amplified.
Ill—4.1 Biopanning
Several attempts were made to determine the optimum procedure for isolating anti-CD41 
reactive antibodies from the phage library by biopanning.
The group was divided into two parts. In the first, the helper phage (VCSM) was added to the 
E. coli (K12) cells and incubated for 15 minutes at 37 °C, and then shaken for 60 minutes. In 
the second group, after adding VCSM immediately the cells was shaken at 37 °C for 60 
minutes without incubating. All cells were biopanned and the number of colonies obtained 
after each round was recorded(section II.8).
The number of washes of the microwells was also studied. Wells were washed either one or 
five times each with a solution of 0.05% Tween 20 in PBS.
These experimental conditions are shown in Table III—1. The results suggest that incubation 
of the cells with addition of helper phage, followed by five times washes the microplate are 
suitable conditions for the remaining experiments.
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Table III—1 The number of the colonies in the biopanning on different condition of 
incubating
Incubation Number
washes
Number of colonies after each round of Biopanning 
R1 R2 R3 R4 R5
Gro
A
Incubate 1 3 18 225 >1000 >1000
Incubate 5 3 3 12 65 237
Gro
B
None 1 3 0 0 0 0
None 5 5 0 0 0 0
Table III—1 Effect of incubation, shaking and number of micro well washes on biopanning of 
E. coli preparations. Cells were either incubated for 15 minutes at 37 °C, followed by shaking 
60 minutes, and other group was shaken for 60 minutes at 37 °C without incubation.
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During five rounds of biopanning, the enriched phage was monitored by counting the phage- 
infected colonies at the end of each round. Fig. Ill—7 shows the number o f colonies isolated 
after each round. The number of colonies increased after each round, suggesting that the 
concentration of the phage potentially bearing anti-platelet Fab increased after each round.
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Figure ff l-7  Number of colonies obtained from consecutive rounds of the biopanning
against whole platelet
Figure HI-7 Number of enriched potentially anti-platelet Fab bearing phage (number o f 
colonies) after each round of biopanning.
The specificity o f the isolated phage of each round was also examined for reactivity with 
platelet proteins using whole-platelet ELISA (section II. 11.2). As can be seen from the graph 
(Fig. Ill—8), the absorbance was increased after each round of biopanning, indicating that the 
concentration of the phage potentially bearing anti-platelet Fab increased after every round.
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Figure III—8 The specificity of the isolated phage of each round against whole-platelet 
Ag
Figure III—8 Reactivity (absorbance) o f the isolated phage against platelet Ag after each 
round of biopanning using whole-platelet ELISA. In this experiment, 100 pi o f whole 
platelets (107 /well) was used (section II. 7).
Data represent the mean (± SE) absorbance o f two experiments. Two wells were used for each
experiment.
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Ill—4.2 Specificity of the Isolated Phage
A hundred individual colonies isolated from the phage pool obtained after five rounds of 
panning  were examined for reactivity against platelet proteins using the whole platelet 
ELISA. These colonies o f phage isolated from the fifth round of panning were randomly 
selected and 109 colony forming units (c.f.u.) of phage were added to each well. The anti­
phage antibody was employed to detect the binding of this phage to platelets (section II. 11.4). 
Of these hundred colonies, just twelve reacted with whole platelets. These were SI, S2, S3, 
S5, S7, S8, S9, SI 1, S12, S14, S18 and S20.
Fig. Ill—9 shows that the amount of reactivity of the 12 colonies for binding with whole 
platelets. M13 (helper phage) was used as a negative control and anti-CD41 as a positive 
control. PBS was the blank. Most of the colonies had absorbance between 0.5 and 0.6, with 
the highest reactivities against whole platelets being seen around absorbance of 0.6.
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Figure III-9  Reactivity of the isolated phages from 12 individual colonies after five
rounds biopanning against platelet proteins using whole platelet ELISA.
Figure III—9 Whole-platelet binding activity (absorbance) of 12 colonies isolated after five 
rounds of panning, plus a negative control (Ml 3), a positive control (anti-CD41) and a blank 
(PBS). In this experiment, 100 pi of whole platelets ( 107/well) was used (section II. 7).
Data represent the mean (± SE) absorbance of two experiments. Two wells were used for each
experiment.
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I l l—4-3 Titration of Isolated Phage Against Whole Platelet
Two of the high-reacting isolated phage colonies, S7 and S9, were used to test reactivity 
against whole platelets in a titration experiment. They were serially diluted from 1 in 100 to 1 
in 800, then 100 pi of each dilution was added to the wells so that the degree of phage­
binding could be detected with an anti-phage antibody. Fig. Ill—10 shows the binding activity 
of these two phage colonies to whole platelets at different dilutions. Both colonies show a 
decrease in reactivity (absorbance) for whole platelets as phage concentrations get lower. This 
shows that the activity is concentration dependent.
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Figure III—10 Reactivity of two isolated phage against platelet protein at different
concentration using whole platelet ELISA
Figure III—10 Effect of dilution of phage from two reactive colonies (S7 and S9) on binding 
(absorbance) to whole platelets. Data represent the mean (± SE) absorbance of two 
experiments. Two wells were used for each experiment.
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Ill—4.4 Binding of Isolated Phage from Biopanning Against Platelet Lysate
The twelve colonies that showed strong reactions against whole platelets were analysed to 
determine their degree of binding to the lysate rather than the platelet. Microtitre plates were 
coated with 100 pi of the platelet membrane lysate at a concentration of 200 pg/ml, and 
100 pi of phage was added to each well. Anti-phage antibody was used to detect the degree of 
binding to the platelet lysate. The results showed that only four colonies from 12 colonies, 
which reacted with whole platelets, showed substantial reactivity against platelet lysate. S7 
showed highest binding to both platelet lysate and whole platelet (Fig. Ill—11).
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Figure: III—11 Reactivity of isolated phage from biopanning against platelet protein
using platelet lysate ELISA
1.4
s9 s8 s2 S7 Positive Negative
Colonies
Figure: III—11 Reactivity (absorbance) against platelet lysate of phages from four colonies 
isolated by biopanning. In this experiment, 100 pi of platelet protein (200 pg/ml) was used 
(section II.5). Anti-CD41 and M13 were used as control positive and negative respectively.
Data represent the mean (±SE) absorbance of three experiments. 2 wells were used for each
experiment.
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Ill—4.5 Reactivity of Phage Isolated from ITP Library against Purified Platelet 
Glycoprotein Ilb/IIIa Complex
The most likely candidate for the antigen recognised by the Fab bearing phages is the platelet 
glycoprotein GP Ilb/IIIa complex. The colonies that showed strong positive reactions against 
platelet antigens (S2, S7, S8 and S9) were also used to determine their specificity against 
GP Ilb/IIIa. Each well o f microtitre plate was coated with 100 pi of purified glycoprotein 
GP Ilb/IIIa at a concentration of 2 pg/ml. Then 100 pi of 109 of Fab-bearing phage was added 
to each well with anti-phage antibody to detect their specificity. Figure III—12 demonstrates 
the reactivity o f phage colonies S2, S7, S8 and S9 against the purified GP Ilb/IIIa complex. 
The results show that the selected colonies reacted strongly with the GP Ilb/IIIa complex 
compared with the negative control (Ml 3 helper phage), with S7 having the highest reactivity, 
and S2 the least.
Page | 144
Figure III-12 Reactivity of isolated phage from biopanning against purified platelet
glycoprotein Ilb/IIIa complex using ELISA assay
1.4
s9 s8 s2 S7 Positive Negative
Colonies
Figure 111-72 Reactivity (absorbance) of antiplatelet Fab antibody against purified platelet 
glycoprotein Ilb/IIIa complex in four phage colonies. In this experiment, 100 pi of purified 
Ilb/IIIa complex (2 pg/ml) was used (section II.5).
Comparison is made with a positive (anti-CD41) and negative control (M l3). These data 
represents the mean absorbance (± SE) from two experiments. Three wells were used for each 
determination in each experiment.
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Ill—5 Identification of Isolated Phage Reactivity against Platelet Proteins by Dot Blotting
Further characterisation of the antigen recognised by colonies S2, S7, S8 and S9 was carried 
out by dot blotting, simply to determine the presence of anti-platelet Fab in the phage. The 
size o f the dot may vary and will relate in a non-quantifiable way to the amount o f the target 
protein present (section II. 12.1). In this experiment, samples from the four colonies were 
spotted onto a membrane and hybridised using an antibody probe .The results in Fig. Ill—13 
show that four selected colonies reacted strongly with the platelet lysate used for dot blotting, 
when compared with the positive control (anti-CD41). The strongest reactions overall were 
seen with S9 and S7 as can be seen in Fig. III-13A The positive control result using anti- 
CD41 is shown in Fig. III-13B.
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Figure III-13 Reactivity of isolated phage from biopanning against platelet protein using
dot blotting
A: S9, S7, S8, S2
Neg S9 S7 S2 S8
B: CD-41
Diluted CD-41 (1/10 with PBS)
Figure III—13 Dot blotting of human platelet lysate reacting against four Fab-bearing phage 
colonies (S2, S7, S8 and S9) compared with the positive (anti-CD41), and Negative (5% 
BSA) controls.
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The antigen recognised by colonies S2, S7, S8 and S9 was further characterised by western 
blotting. This analytical technique can detect specific proteins in a given sample of tissue 
homogenate or extract, by using gel electrophoresis to separate native or denatured proteins 
according to the length of the polypeptide. The proteins are then transferred to a nitrocellulose 
membrane or polyvinylidene fluoride (PVDF) membrane, where they are probed by 
antibodies specific to the target protein. In this experiment, 20 pi of platelet lysate at a 
concentration of 200 pg/ml was loaded onto an 8% polyacrylamide gel. Electrophoresis was 
performed and it was then transferred onto nitrocellulose paper (section II. 12.2). Lanes S2, 
S7, S8, and S9 are the anti-platelet Fab bearing phage which reacts with platelet lysate.Lane N 
is a negative control (M13) and lane P is positive (GPIIIa) control. At room temperature of 
15-22 °C) three bands with different molecular weights were identified by the S2, S7, and S8 
colonies of isolated Fab-bearing phages, and only one band was detected for the phage of the 
S9 colony. Molecular weights 92kD and 116kD are the same GpIIIa, and GPIIb respectively. 
The minor bands are more likely break down of platelet glycoprotein.
These results are shown in Fig. Ill—14
I l l—6 Identification of Isolated Phage Reactivity Against Platelet Proteins by W estern
Blotting
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Figure III-14 Reactivity of isolated phage from biopanning against platelet protein using 
western blotting developed by ECL.
Figure III—14 Western blotting of non-reduced human platelet lysate reacting against four 
Fab-bearing phage colonies (S2, S7, S8, S9) along with negative (Ml 3 helper phage) and 
positive (anti-CD41) controls. The first four lanes are the platelet protein bands for the four 
colonies. Lane N is the negative control and lane P is the positive control.
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III-7 DNA gel agarose
In order to determine that heavy and light chains were present in the phage, DNA of the four 
phage colonies with stronger reactions to platelet protein were analysed. Again these were the 
colonies S2, S7, S8 and S9. A plasmid isolation kit was used to isolate DNA from phage 
grown in Luria broth. The purified DNA from each phage colony was cut with a restriction 
enzyme and loaded onto an agarose gel before undergoing electrophoresis (section II. 10.3). 
The results demonstrated the presence o f a DNA band of 5.4 kbp (base pairs) in size. The 
figure shows the presence of library phage DNA of the correct molecular weight (Fig. Ill—15).
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Figure m -15 Purity of phage DNA
4kbp
Figure III-15 Purified DNA of the four the phage run on a 1% agarose gel. The four 
indicated bands (S2, S7, S8, and S9) co-migrated with the 5.4kbp DNA molecular size 
marker.
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SECTION IV: DISCUSSION
The thrombocytopenia in ITP characterised by the destruction o f platelets in the circulation by 
antibodies. These antiplatelet antibodies react with various autoepitopes on the glycoprotein 
complexes, located on the external membrane of platelets, which are the focus o f the present 
study.
IV-1 ELISA of antiplatelet Antibodies
In the initial stages of the study, a quick and sensitive ELISA assay was developed for 
analysing whole washed platelets and frozen platelet lysate from healthy volunteers, in order 
to identify and quantify the binding of antiplatelet antibodies relevant to the disease ITP. All 
the glycoprotein subunits on platelets can act as antigens to autoantibodies, but the complexes 
commonly affected in chronic forms of ITP are the highly immunogenic GP Ilb/IIIa and 
GP Ib/IX complexes (Van Leeuwen 1982; Beardsley 1984; Woods 1984; Yanabu 1991). 
Around 75% of antiplatelet antibodies in ITP are against antigens on the GP Ib-IX complex, 
and anti-GP Ilb/IIIa autoantibodies occur in approximately 15% of ITP patients (McMillan 
2000). It was expected during this study that any antibody reactivity would be directed against 
one of these types of glycoprotein receptors.
The initial ELISA studies focused on the adhesive protein receptor complex known as 
GPIIb/IIIa, which is associated with two antigens, namely the CD41 antigen and the CD61 
antigen. The GP lib complex is the CD41 antigen and the GP Ilia complex is the CD61. A 
reaction was only obtained for anti-CD41, so the subsequent experiments were based on the
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use of anti-CD41 as control positive. Throughout this discussion, antibodies against the GPIIb 
complex will be referred to as anti-CD41.
The GP Ilb/IIIa complex is of particular significance in ITP as it is also the fibrinogen 
receptor, which is essential for maintaining normal haemostatic functioning o f the body 
(Beutler 1995; Stiene-Martin 1998). Circulating platelet counts decrease through 
autoantibody-mediated destruction when the glycoprotein receptors are seen as antigens, and 
disruption of this complex also alters the platelet response to injury. The overall result is the 
development of bleeding disorders such as purpura and prolonged bleeding time, as seen in 
ITP.
Having established the presence of glycoprotein antigens in the human platelet samples, 
various parameters were investigated for optimum performance in the ELISA experiments. 
These included the choice o f blocking buffer. Different kinds o f blocking buffers were 
investigated to find the most appropriate one for use in subsequent ELISAs experiments. The 
buffer which gave greatest absorbance difference between positive and negative control was 
5% dried milk in PBS (Fig. Ill—1).
The platelets from the healthy volunteers were prepared in two ways -  as a whole platelet 
preparation or as a lysed platelet preparation. The amount of protein contained in the lysate 
was determined using a modified Bradford assay (Bradford 1976). Every ml o f lysate was 
found to contain 1400 pg protein (Fig. Ill—2). The value of 200 pg protein per ml was used in 
all subsequent experiments, which it is the same amount of protein of 107 whole platelet per
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well (Kelton 1983). This protein would have included antigens such as CD41 and other 
glycoproteins, as well as other non-glycoprotein proteins.
IV-2 ELISA of Antiplatelet Fab Antibody Fragments
ELISA was also used to detect potentially Fab-binding platelet glycoproteins phages. This is 
because antibody binding to glycoprotein complexes in platelets can be Fab-mediated 
(Strieker 1986), whereby the Fab-binding part of the glycoprotein binds to the Fab region o f 
the paratope on the antibody.
To detect these platelet Fab-binding glycoproteins, it was necessary to quantify the optimum 
concentrations of anti-CD41 antibody to use in the ELISA experiments. The optimum 
concentration was therefore determined using mouse monoclonal anti-CD41 antibody and 
washed whole platelets (Fig. Ill—3). It was found to be 10'2 pg/ml.
Then the optimum concentration o f whole platelets to use in ELISA experiments was found. 
Whole platelet preparations in a range of concentrations were tested against anti-CD41 
antiplatelet antibody, and a maximum reaction was observed with 107 platelets per well. This 
whole-platelet concentration was used in all subsequent ELISA assays.
The optimum concentration o f platelet lysate for detecting anti-CD41 was determined to be 
1400 pg/ml (Fig. Ill—5) that it was used at 200 pg/ml throughout the study.
These optimum concentrations o f whole platelets and lysate were used to determine whether 
whole platelets or lysate were more suitable as a substrate in the binding assays of antibodies 
and platelet antigens. Whole platelets were expected to adsorb more antibodies against
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glycoprotein complexes, not least because antiplatelet antibodies can only attach to cation- 
dependent epitopes on the GP Ilia component if  the complex is conformationally intact 
(McMillan 2000), or because the complex on the platelet surface may undergo a 
conformational change that causes it to be displayed differently on activated platelets and 
express new epitopes (Wagner 1996).
In the ELISA analysis o f the platelet glycoprotein Ilb/IIIa complex, using monoclonal anti- 
CD41 antibodies, the anti-CD41 antibody reacted most strongly against CD41 antigen in the 
whole platelet preparation, as expected, compared with the antigen in the lysate preparation 
(Figure III-6). The reaction of the lysed platelets was only 70% of that seen with the whole 
platelet preparation. There may be several reasons for this. First, the amount o f CD41 antigen 
may have been greater in the whole platelet preparation because there may have been 
different amounts o f protein in the two kinds o f samples. Only the protein content in the lysed 
preparation was determined in this experiment. The protein content of the whole platelet 
sample may have been different, which meant the two samples could not be directly compared 
and no assumptions could be made about the amount of CD41 antigen they contained. As a 
consequence, any differences in the reactivity o f the samples in this study had to be treated 
with caution.
Second, the differences obtained with the different preparations might have arisen because of 
changes occurring during the preparation of the lysed platelets. Lysis may release non­
membrane proteins and expose new antigenic epitopes. The glycoprotein complexes may 
remains intact on the surface of the platelet, and some become detached from the platelet
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membranes and undergo some conformational change. Evidence suggests that some 
complexes are better recognised by antibody when they are still in situ on the surface o f the 
platelet.(McMillan 2000), for example, showed that antiplatelet antibodies only attach to 
cation-dependent epitopes on the GP Ilia component when the whole GP Ilb/IIIa complex is 
conformationally intact.
IV-3 Isolation of Antiplatelet Fab Fragments
Antiplatelet Fab fragments specific for the glycoprotein complex were isolated from a phage 
library by a procedure known as biopanning, which involves several steps. The biopanning 
experiments used whole platelets, rather than lysed platelets, largely because the response of 
autoantibody in ITP is against several glycoproteins or antigens on the surface o f the platelet 
(Smith 1994).
First, a phage display library was prepared from a Fab-expressing phagemid library of human 
immunologlobulin light and heavy antibody chains on the V domain, constructed from the 
mRNA from the splenic B lymphocytes of a patient with ITP, using cDNA encoding for 
immunoglobulin mostly IgG. IgG is associated with the chronic form of ITP (Shulman 1965; 
Shulman 1965; McMillan 1974; Schwartz 2007), and IgG-specific autoantibodies can be 
detected in as many as 60% of ITP patients (Coopamah 2003)with levels of platelet-binding 
IgG being shown to increase (McMillan 1974; Semple 1998).
In this study, PCR-amplified gene segments for the antibody domains which were cloned into
PAK100 vectors (Krebber 1997). The desired gene segments were inserted into the phagemid
of the Escherichia coli and the gene product was displayed on the surface o f the
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bacteriophage. During the capturing step, the phage library was conjugated to the desired 
target, so that only specific peptides presented by bacteriophage were bound to the target. The 
bacteria that took up copies o f the plasmid became resistant to certain antibiotics, and on 
exposure to a particular antibiotic, the resistant bacteria survived. These bacteria were grown, 
harvested and lysed to isolate the plasmid of interest. Any phages that did not bind to the solid 
surface are washed away, leaving phages with strong binding affinity. The more times the 
preparation was washed after each round of panning resulted in the removal of more unbound 
phage, without significant loss of specifically bound phage.
The library underwent sequential panning with whole platelets from the healthy volunteers, 
and resulted in the isolation o f glycoproteins that recognised the phage specifically. Phage- 
recognising platelet antigens that bound the Fab fragments were isolated and the attached 
phage was recovered and amplified and used to infect more E. coli. The more times this was 
done, the stronger the affinity of the binding peptides to the target.
In order to isolate maximum numbers of potentially anti-platelet antibodies, the biopanning 
procedure was carried out under different conditions, with either incubation or shaking 
immediately after adding VCSM helper phage, and with different numbers o f washes after 
each round of biopanning. This study revealed that the number of colonies obtained was 
maximal with incubation rather than shaking and with five washes after each round of 
biopanning (Table IV-1).
Five rounds of biopanning were carried out. Each round produced higher numbers of enriched 
antiplatelet antigen-specific Fab-bearing phage. The amount was quantified as colony­
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forming units (c.f.u.) as shown in Fig. Ill—7. The first round of panning produced only three 
clones from a 109 c.f.u./ml phage suspension. After five rounds there were 237 colonies. The 
quantity of starting phage was not significant.
It was expected that these increasingly large numbers colony-forming units would have 
increased levels of anti- Fab- bearing phage. The specificity of the enriched phage in each 
round of panning was therefore tested for reactivity against platelet protein ELISA was used 
to confirm that the amount of phage potentially bearing anti- Fab increased after each round 
of panning, reaching a maximum after the five rounds.
The reactivity of a number of colonies after five rounds of panning was investigated next. A 
hundred colonies were isolated from the phage pool, which randomly were selected. From 
each of these, 109 c.f.u. of the phage were added to a well with anti-phage antibody and 
examined for reactivity against platelet proteins using the whole-platelet ELISA. Twelve of 
the hundred colonies showed reactivity against whole platelets, as shown in Fig. Ill—9. All of 
the twelve reacting colonies showed a high level of reactivity with whole platelets compared 
to the negative control M l3 phage (Fig. III-9). The same study showed that 23 out o f 40 
randomly selection colonies reacted with GPIIb/IIIa that their inhibition studies using murine 
mAb against various epitopes suggested that binding epitopes of phage antibodies were 
located within the GPIIb/IIIa complex. They used the phage display approach to isolate Fab 
antibody fragments recognizing native GPIIb/IIIa.A library from a human donor immunized 
with Rh+ red blood cells was panned with freshly washed platelets.(Escher 1998).
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IV.4 Identification the phage expressing anti platelet antibodies by platelet lysate
The phage colonies that showed a positive reaction against whole platelets were analysed to 
determine their binding to platelet lysate. The microtitre plates were coated with 100 pi o f the 
platelet membrane lysate at a concentration o f 200 pg/ml. The results showed that just the 
colonies S2, S7, S8, and S9, which strongly reacted with whole platelet, also reacted with 
platelet lysate when compared with negative control (M l3), however these reactions are less 
than the reaction against whole platelets. S7 showed highest binding to both platelet lysate 
and whole platelet. After that, those colonies which showed a strongly positive reaction 
against platelet lysate were analyzed to determine their specificity against purified GPIIb/IIIa. 
Each well of microtitre plate was coated with 100 pi of purified glycoprotein llb/IHa at a 
concentration o f 2 pg/ml. The result show that the selected colonies, which reacted strongly 
with whole platelets and platelet lysate, also reacted strongly with the GPIIb/IIIa complex.
IV-5 Identification of the reactivity of the isolated phage against platelet proteins by Dot 
blotting
Further characterisation o f the proteins in the platelet lysate was performed by blotting 
techniques. Dot blotting was used to detect the presence of anti-platelet Fab in four high- 
reacting Fab-bearing phage colonies. All four colonies reacted strongly with the platelet 
proteins in the lysate, as shown in Fig. 113—13. This semi-quantitative analysis revealed 
nothing other than the presence of the target molecule, giving no information about its 
properties, such as its molecular weight. Therefore western blotting was also performed on the 
phage colonies.
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The ability o f the same four Fab-bearing phage colonies to recognise platelet antigens was 
evaluated by quantifying the amount of protein through the non-reducing conditions of 
western blotting. This technique detects specific proteins in a sample using gel electrophoresis 
to separate them according to their molecular weight. In this experiment, samples from the 
four phage colonies were spotted onto a membrane and hybridised using an antibody probe. 
Three of the four colonies examined showed three bands. The bands represented proteins with 
several different molecular weights, including one of 92 kD. The fourth colony contained 
protein in just one band, and this band corresponded to a molecular weight of 92 kD. This 
means that all four colonies contained a protein with the same molecular weight as the 
positive control, that is 92 kD (Fig. Ill—14). The molecular weight of the glycoprotein GP Ilia 
subunit is between 88 and 95 kD (Kokawa 1993) so this experiment suggests the reactive 
protein in the four phage colonies was the GP Ilia glycoprotein subunit found in human 
platelets.
The final experiment to characterise the protein isolated from the phage library was a DNA 
gel agarose test. This was conducted on DNA isolated from the four high-reacting phage 
colonies. Each colony showed a DNA band that corresponded with the molecular size marker 
for 5.4 kbase pairs (Fig. Ill—15), and this suggested the presence of heavy and light antibody 
chains in the phage.
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SECTION V: CONCLUSIONS
This study used a random selection o f phage library colonies to produce Fab antiplatelet 
antibodies that showed reactivity for certain antigens on the surface of human platelets. This a 
phage library was derived from a patient with the autoimmune disease ITP. ELISA was used 
to show that the isolated Fab fragments reacted with antigens on the platelet surface. Future 
studies could be conducted to isolate additional Fab antibody fragments. Further analysis and 
modification of the fragments isolated in this study, and other Fab fragments isolated in the 
future, will improve our understanding of the platelet antigen-antibody interaction in the 
autoimmune disease of ITP.
There are numerous problems associated with the diagnosis of ITP, because the main features 
o f the disease (thrombocytopenia and bleeding disorders) are not specific to this disease 
alone. Diagnosis must rely on laboratory findings (Brighton 1996) and the elimination of 
other causes of thrombocytopenia. Although some antiplatelet antibody assays have high 
specificity and accuracy, such as the MAIPA (Wadenvik 1998; Winiarski 1998), these assays 
are more suitable for monitoring disease severity rather than diagnosis. Any studies that 
further characterise the autoantibodies against platelet glycoproteins in ITP are likely to 
contribute to the body of evidence for making a more accurate and specifi clinical diagnosis, 
by helping to discriminate between the thrombocytopenia seen in ITP and thrombocytopenia 
that arises in other disease. Ultimately elucidating mechanisms behind the formation antigen- 
antibody complexes in ITP may offer new means of targeted therapy in the future.
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VI. Future work
Further characterisation of the Fab can be undertaken by sequencing the DNA. This enables an 
understanding of the genetics of the expressed Fab repertoire (Chang 2001). It also gives a 
chance to study the mechanisms underlying the production of autoantibodies and structure 
motifs involved in antigen recognition. The DNA sequences from 4 colonies can show then- 
sequences that these colonies have the same sequence and refer from one anti-platelet Fab or 
not. In one study DNA analysis from 23 phages which reacted against GPIIb/IIIa, identified 
only three Fabs (Escher 1998), which may suggest that patients with an immune response to GP 
Ilia may shows a small range of antibodies.
Additional isolation, analysis and modification of this antibody fragment holds potential for 
understanding key aspects of the platelet antigen-antibody interaction.
1- With manipulation of Fab bearing phage by further panning and selection of different 
colonies a more specific and higher affinity of Fab might be obtained.
2- By synthesising the peptides based on the RSD motif to analyses, their ability to inhibit 
platelet aggregation using aggregometer.
3- The RSD motif on CDR1 amino acid sequence can be used as a basis to develop therapeutic 
agents.
4- Site directed mutagenesis to analyse the role of individual amino acids in determining Fab 
binding to GPIIIa.
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